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ABSTRACT OF THE DISSERTATION 
 CAROTENOIDS AND FATTY ACIDS IN EARLY LACTATION: A STUDY OF A 
PERUVIAN POPULATION 
by  Vanesa Mendez  Florida International University, 2016  Miami, Florida  Professor John T. Landrum, Major Professor  
Lipid soluble carotenoids are micronutrients present in human milk that serve as 
precursors of vitamin A and also play an important role protecting cells from damage 
arising from photooxidative processes and reactive oxygen species.  Fatty acids comprise 
about 3-5% of human milk and are mainly present as triglycerides.  They are a major 
energy source for the infant and are necessary to support cell growth required for normal 
development and maturation of critical organs.    Transport of carotenoids into milk has 
been little studied and there has been no previous investigation of the relationship of 
carotenoid transport with that of individual fatty acid secretion into milk.  
In the present study, levels of the carotenoids, lutein, zeaxanthin, -cryptoxanthin, 
and -carotene, in maternal serum, infant cord blood, and milk obtained from 74 
Peruvian mothers were measured by HPLC methods.  The fat content and fatty acid 
profile of maternal milk were determined by GC-FID and confirmed by GC-MS.  Twenty 
nine fatty acids were identified and quantified after conversion to methyl esters. 
vi  
Statistical analysis was employed to investigate potential trends and relationships among 
the carotenoids in all three fluids as well as between carotenoids and fatty acids present.  
Concentrations of lutein in maternal serum and milk as well as maternal serum 
and infant cord blood were highly correlated (r=0.43, p<0.03) and (r=0.40, p<0.05), 
respectively.  Body mass index was inversely correlated with the concentration of pro-
vitamin A carotenoids in milk and serum.  Carotenoid concentrations declined during the 
initial weeks of lactation and did not significantly correlate with fat content which 
remained constant.  Concentrations of essential n-3 and n-6 fatty acids were found to be 
in the upper quartile among others populations studied worldwide.  An inverse 
correlation between lutein and the concentrations of linoleic acid (r=-0.432, p<0.02) and 
α-linoleic acid (r=-0.435, p<0.02) present in transitional milk was seen.  Moreover, 
secretion of carotenoids into milk shows a positive correlation with a small number of 
fatty acids that are metabolically produced within the mammary duct.  A competitive 
relationship between the transport of these essential polyunsaturated fatty acids is 
hypothesized to play a role in the secretion of early milk but not that of mature milk.   
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CHAPTER I: Carotenoid properties, functions and bioactivity influence in the human body 
 
Carotenoids exist in nature as pigments in microorganisms and plants.  They are 
synthesized in plants, fungi, bacteria and algae, therefore these compounds are considered 
essential for life since they actively participate in the process of photosynthesis [1]. 
Carotenoids are responsible for the coloration in many flowers, fruits and vegetables and 
they are also the principle pigments in various animals: fish, birds’ feathers and 
crustaceans [2].  Humans cannot synthesize carotenoids but they can obtain them from 
their diet and use them as antioxidants.  In early life, newborns acquire these 
micronutrients during lactation and they are important for their development.  More than 
750 of these compounds had been identified in nature [3], but only 33, including 
geometric isomers and metabolites,  have been detected in human plasma tissues, and 
breast milk [4, 5] . 
 
1.1. Carotenoid Biosynthesis [6, 7]  
In plants, carotenoids are a family of pigments that participate in light harvesting 
and are essential for photoprotection against excess light.  Carotenoids are synthesized in 
the plastids by enzymes that are encoded by the nucleus. Carotenoids are built from the 
biological isoprene precursor isopentenyl pyrophosphate (IPP).  The first specific 
terpenoid precursor is mevalonic acid (MVA).  Mevalonic acid is converted into IPP by 
means of a three step enzymatic pathway; each step requires one mole of ATP per 
substrate. The first step is regulated by MVA kinase as been demonstrated in plant 
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species and microorganisms. The identity of MVA-5-pyrophosphate, the product 
resulting from the second step, has been evidenced in yeast and has been identified as an 
intermediate in a bacterial system that can convert MVA into carotenes.  Isopentenyl 
pyrophosphate can be found in enzymatic systems capable of carotenoid synthesis, such 
as tomato fruit. 
  
 
Figure 1. Formation of IPP from MVA 
 
To continue chain elongation, IPP is isomerized to dimethyl lallyl diphosphate 
(DMAPP) in the first step by the enzyme IPP isomerase [8] (See Figure 1). The 
sequential addition of three IPP molecules to DMAPP, lengthens the chain to 10 carbons. 
Formation of the C15 molecular intermediate (FPP) is catalyzed by the enzyme 
geranylgeranyl diphosphate synthase (GGPS) that links DMAPP. The enzyme is one 
member of a family of closely related prenyl transferase enzymes distinguished by the 
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length of the final product. The 20-carbon molecule geranyl geranyl pyrophosphate 
(GGPP) is generated by two identical C5 addition steps. 
 
CH2OPP IPPIPP
C5
CH2OPP GPPIPP
C10
CH2OPP
CH2OPP
IPP
GGPP
C15
C20
C40
PSY
GGPS
FPP
GGPP
phytoene  
Figure 2. General pathway for the formation of phytoene [7]. The arrows on the side represent the enzymes involved. GGPS: geranylgeranyl diphosphate synthase. PSY: phytoene synthase. 
 
The next step in the carotenoid pathway is the condensation of two GGPP 
molecules to produce phytoene, which is catalyzed by a membrane-associated enzyme, 
phytoene synthase (PSY).  Phytoene synthase shares amino-acid sequence similarity with 
GGPP synthase and other prenyl-transferases [8]. The condensation of two molecules of 
farnesyl pyrophosphate to produce squalene, the C30 precursor of sterols, is similar to the 
formation of phytoene from geranylgeranyl diphosphate synthase. In the biosynthesis 
pathway, NADPH is not required and one hydrogen is lost from C1 of each of the 
participating GGPP molecules. The GG residues are linked via sulphonium ylide. 
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Four desaturation steps are required for the conversion of phytoene to lycopene 
and are catalyzed by two related enzymes in plants: phytoene desaturase and ζ-carotene 
desaturase. However, bacteria and fungi achieve the same result via a single enzymatic 
complex. The first desaturation of phytoene produces phytofluene; then phytofluene 
undergoes dehydrogenation and isomeration to be converted into ζ-carotene. ζ-carotene is 
subsequently desaturated to produce neurosporene and lycopene. In the end, the four 
reactions build the conjugated carbon backbone of lycopene. 
 
 
Figure 3. General pathway for the formation of lycopene [7]. The arrows on the side represent the enzymes involved. PDS: phytoene desaturase. ZDS: ζ-carotene desaturase. 
 
At this point in the biosynthesis, the pathway branches and the cyclization of 
lycopene may occur to produce either β- or ε-ring end-group structures. One branch leads 
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to the formation of β-carotene and its derivative xanthophylls, and the other branch leads 
to α-carotene and lutein. ε-carotene is also produced from δ-carotene. 
 
 
Figure 4. Cyclization of lycopene. Enzymatic conversions are shown by arrows with the enzymes responsible. LCY-β: lycopene beta-cyclase; LCY-ε, lycopene epsilon-cyclase; CRH-β, β-carotene hydroxylase; CRH-ε, epsilon-carotene hydroxylase [8]. 
 
During the biosynthesis of the cyclic carotenoids, the formation of ε- and β-
ionone rings take place at a late stage in the pathway. Experiments indicate that the β-
ionone ring is formed by a mechanism that involves a carbonium ion (Figure 5). The 
cyclization concludes with the release of the HB proton from the C-6 ε-ionone is also 
formed by via a carbonium ion but in this case it is stabilized by expulsion of the HA 
proton at C-4. 
During the cyclization of lycopene, the reactions that are necessary for the 
formation of the carotenoid end-groups in both branches (the one that leads to lutein and 
the other that leads to zeaxanthin, Figure 4) are dependent on the relative activities of the 
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cyclases involved in the reaction. The most common xanthophylls in the green tissue of 
higher plants, algae, and non-photosynthetic bacteria have hydroxyl substitutents at C-3, 
an oxo at C-4 or an epoxy at the 5, 6 position of the ionone ring [9]. Genetic evidence and 
functional analysis of an Arabidopsis β-hydroxylase enzyme support the existence of 
separate hydroxylases specific for the β- and ε-rings.  
 
 
Figure 5. Basic mechanism for biosynthesis of ε and β-rings in carotenoids. 
 
1.2. Carotenoid structures 
Carotenoids are tetraterpenoids that contain eight isoprenoid units [6], Figure 6. 
They have a C40 carbon skeleton.  Isoprenoid units link together in a head to tail pattern 
to form two C20 fragments that are again linked together in a head to head fashion at the 
center to form a carotenoid unit. Therefore, neighboring methyl groups of the polyene 
chain are six carbons apart from each other at the chain center but only 5 carbons apart in 
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rest of the molecule.  As shown in the previous section, all C40 carotenoids are derived 
from lycopene by synthetic pathways that include: cyclization, oxygen insertion, double 
bond migration, methyl migration, chain elongation, and chain shortening [6]. 
 
 
 
 Figure 6. Carotenoid structure. A) Isoprene unit.  B) C40 Structure of Lycopene. 
 
Figure 7. Carotene numbering system. 
 
Traditionally, carotenoids can be grouped into two classes: (a) carotenes or (b) 
xanthophylls. Carotenes are hydrocarbons (example: lycopene or β-carotene). 
Xanthophylls have oxygen atoms in their structure (example: lutein and zeaxanthin) [10].  
For carotenes, all specific names are based on the stem name “carotene”, which 
corresponds to the structure and numbering shown in Figure 7.  
 
A 
B 
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Figure 8. Carotene (β-carotene) and Xanthophylls (lutein and zeaxanthin). 
 
Table 1. End-Group Designations of Carotenes. 
Type Prefix Structure 
Acyclic  (a) 
Cyclohexene β,  (b, c) 
Methylenecyclohexane δ (d) 
Cyclopentene ε (e) 
Aryl ,  (f,g) 
 
Structurally, the carotenoids possess end-groups that are either acyclic or rings of 
five or six carbons at one or both ends of the molecule. Carotenes are named according to  
the end group(s) that are present in their structures[6].  The end-groups and their prefixes 
are indicated in Table 1. 
In green tissues, algae, and many fungi the major carotenoids are cyclic 
compounds such as: β-carotene and α-carotene. The carotenes mentioned contain ionone 
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rings in their structure. β-carotene has two β-ionone groups and α-carotene has one ε-
ionone and one β-ionone ring.  
 
Figure 9. End-groups structure 
 
In xanthophylls, which contain oxygen functional groups, the compounds are 
named according to the usual IUPAC nomenclature rules, indicating the position of the 
oxygen containing substituent. For example, the name of zeaxanthin (see Figure 8) is β,β-
carotene-3,3’-diol. 
The conjugated double bonds present in the structures of carotenoids give them 
the possibility to exist as several “cis-trans” geometrical isomers.  Usually, cis and trans 
are used to indicate the orientation of substituent groups in a molecule relative to a 
double bond.  When there are more than two different substituents on a double bond, E 
and Z are the more correct designations used to describe the geometrical isomerism. In 
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nature, most carotenoids are found in the all-E (trans) configuration.  It is also possible 
for the structures to have one or more “cis” or Z double bonds, but these are energetically 
disfavored.   
1.3. Physical and Chemical properties 
The size and shape of the carotenoid molecule are important in determining its 
properties and functionality.  All carotenoids in the all-trans configuration have an 
extended conjugated double-bond system, in cells they are soluble in the hydrophobic 
components and especially the interior of the cell membrane [11]. Polar xanthophylls are 
known to span the cell membrane, placing the polar hydroxyl groups at the membrane 
surface; whereas more non-polar carotenoids, such as β-carotene take a position fully 
embedded within the hydrophobic interior [12].  The shape of cis carotenoid isomers 
differs from that of the all-trans forms, and consequently their fit into subcellular 
structures is altered.  Carotenoids may be associated with other molecules in the living 
cell such as proteins and lipids, a result of their size, shape, and lipophilicity.  Likewise, 
for some carotenoids, the presence of polar functional groups on their structure gives 
them the ability to interact with other polar molecules.  The presence of carotenoids in the 
cell membrane affects the membrane’s thickness, strength, fluidity, and permeability to 
water, oxygen, and other molecules.  Interactions between carotenoids and proteins are 
common in living organisms [11]. They are associated with the lipid components of 
lipoproteins, which allows them to be transported and to function in aqueous 
environments [11].  In vivo, carotenoids are more stable than when isolated in pure 
compounds, especially when in organic solution.  
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Figure 10. Electronic absorption spectra of different carotenoids (extracted from tomatoe in 80% acetone/diethyl ether). Taken from [13] 
 Most carotenoids are unstable and in the presence of light and oxygen are readily 
degraded.  The ability of carotenoids to absorb light is conferred by the presence of the 
extended conjugation of double bonds present in the polyene chain.  Most carotenoids 
absorb light in regions of the visible and ultraviolet spectrum where few other biological 
compounds absorb.  Many carotenoids show three peaks or two peaks with a shoulder 
absorbance spectrum around 450 nm [13].  Their characteristic visible absorption 
spectrum is principally a consequence of the number of bonds in the conjugated chain but 
is, in addition, modified by other functional groups in the structure.  A result of an 
additional conjugated double bonds is an increase of between 7 - 35nm in the wavelength 
maximum.  [14].  Geometrical isomerization also influences the electronic absorption 
spectra of carotenoids.   
1.4. Antioxidant activity of carotenoids [15, 16] 
Carotenoids have an important role protecting cells and organisms against damage 
by light and reactive oxygen species (ROS) generated by light [17] and allow them to act 
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as antioxidants.  Because of their ability to accept energy through space from neighboring 
excited state species via a quantum coupling mechanism or by collisional interactions and 
to rapidly relax dissipating energy through vibrionic interconversion, carotenoids are very 
effective at quenching and inactivating those high-energy excited states resulting from 
the absorption of short wavelength light by molecules that are capable of activating 
oxygen, particularly hemes, chorophyll, and vitamin A.  Krinsky elegantly explained how 
carotenoids perform as antioxidants by reacting with reactive singlet oxygen generated 
during photosynthesis and in other biological systems exposed to both light and oxygen 
[16]. 
1.4.1 Carotenoid quenching of singlet molecular oxygen (1O2) 
 
Figure 11. Diagram of the electronic states of the O2 molecule. 
When light of the correct energy strikes a biological system that contains an 
appropriate sensitizer (S), the energy of the photon is absorbed and the sensitizer is 
electronically excited, most commonly to produce the 1S, excited state. The singlet 
22 
37 
 
 
1 2nd. excited state 
  life time ~ 1x10-11s  
 
3 ground state  
 
1    1st  excited state 
  life time ~ 3-100µs  
 
O2 *  
O2 *  
O2 *  
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excited states for most molecular species are very short-lived. The lifetime,  for most 
species is measured in nanoseconds (typically 0.1-100 x10-9s).  By intersystem-
crossing the singlet excited states, 1S, can efficiently interconvert to a longer lived triplet 
excited state, 3S (Equation 1).  
S  1S  3S   (1) 
        S+ 
 Type I:  3S +    biomolecule   SH·   (2) 
R·    
Type II:  3S + 3O2   1S + 1O2  (3) 
 
The 3S can initiate Norrish Type I or Type II photochemical reactions. In Norrish 
Type I reactions the triplet initiates radical reactions by abstracting an electron or 
hydrogen atom from nearby biomolecules creating reactive free radical species, Equation 
2. In the Norrish Type II reaction, the triplet sensitizer reacts with molecular oxygen. O2 , 
also a triplet species, to form of the highly reactive 1O2, regenerating the ground-state 
sensitizer, Equation 3, while conserving the total spin of the system as required by 
quantum mechanics. 
Ground state carotenoid interacts readily with 1O2, accepting the excess energy 
and quenching this reactive excited state, Equation 4.  This reaction also conforms to the 
quantum mechanical requirement that net spin be conserved during any allowed process. 
 
1CAROTENOID   + 1O2   3CAROTENOID + 3O2 (4) 
 3CAROTENOID     1CAROTENOID    +      heat   (5) 
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The geometry of the linear conjugated polyene chain confers on the carotenoid 
molecules a large number of closely spaced vibrational energy states that facilitate the 
dissipation of energy from the excited state through vibrational and rotational transitions.  
Coupled with the process of energy transfer involve in intermolecular collisions with the 
solvent energy is readily and harmlessly lost from the excited state carotenoid to the 
surrounding as excess heat. Thus the triplet carotenoids return to their ground state 
unaltered and ready to repeat the process of quenching, Equation 5.  
Lipophilic carotenoids rapidly react with peroxyl radicals competing for free 
radicals generated when free radicals react with oxygen.  Peroxyl radicals are formed 
during lipid peroxidation and scavenging of this species interrupts the chain reaction 
sequence that can rapidly produce extensive damage to unsaturated species in lipophilic 
compartments [18].  Therefore, carotenoids play an important role in the protection of 
cellular membranes and lipoproteins against oxidative damage because of their 
lipophilicity and ability to scavenge peroxyl radicals [19]. 
1.5. Bioactivity and disease prevention 
In humans, carotenoids act as antioxidants by neutralizing the ROS in cellular 
tissues, as described above.  ROS are generated by normal metabolic activity as well as 
photic processes and many environmental and behavioral factors may contribute to their 
formation.  These include smoking, air pollutants, diet, and exposure to either natural or 
industrial chemicals [20].  Studies have demonstrated that carotenoids are positively 
correlated with a reduced risk of many diseases that are associated with oxidative 
  
15  
processes, including some types of cancer, cardiovascular disease, and age-related 
macular degeneration [21], (see Table 2).  Carotenoids may also act to optimize health 
through  mechanisms such as promoting transcription of gap junction proteins and 
associated gap junction communication, effects on regulation of cell growth, modulation 
of gene expression and immune response, and as modulators of Phase I and II drug 
metabolizing enzymes [22].   
In other in vitro studies, β-cryptoxanthin has been found to have a stimulatory 
effect on bone calcification and, osteoblastic bone formation, and inhibitory effects on 
osteoclastic bone resorption.  Moreover, in animal models the intake of β-cryptoxanthin 
appears to have a preventive effect on bone loss leading to osteoporosis and may also 
function in this manner in healthy humans or postmenopausal women [23].  
1.6. Transport and distribution of carotenoids in the human body 
In animal models, the pathway for absorption and metabolism of carotenoids 
starts after the consumption of carotenoids from the daily diet [24].  As mentioned above, 
carotenoids are implicated in the prevention of degenerative diseases.  They have a lower 
bioavailability than other lipophilic components such as α-tocopherol and may be a factor 
that influences their action.  The main cause of this lowered bioavailability is the poor 
solubility of carotenoids in digestive fluids [25].   
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Table 2. Carotenoids, functions and effects associated with prevention of human diseases and optimization of human health (taken from Takana et al.[26]). 
 
Carotenoids are lipid-soluble and follow absorption pathways similar to those of 
other dietary lipids, but the pathway is more complex because there are several additional 
steps.  We should mention here that digestion and absorption of dietary lipids is a 
prerequisite for optimum absorption of carotenoids in the body [26].  Carotenoids are 
incorporated into a complex food matrix that contains proteins and lipids.  After the food 
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matrix is digested, carotenoids are combined with lipids and bile salts in micelles.  The 
polarity of each individual carotenoid influences the extent to which it is incorporated 
into micelles. [27].  The micelles, together with incorporated carotenoids, are captured 
and transported into the enterocyte at the intestinal brush border membrane. Once in the 
enterocyte, micelles are deconstructed and components may be metabolized.  Carotenoids 
appear to be absorbed by the mucosa of the small intestine (mainly in the duodenum) via 
passive diffusion to become packaged into triacylglycerol-rich chylomicrons. 
Carotenoids repackaged in chylomicrons are secreted into the hepatic portal vein leading 
to their transport to the liver for further reprocessing.  Sugawara et al.[28] investigated 
the absorption of 15 different carotenoids solubilized in mixed micelles in differentiated 
Caco-2 human intestinal cells, as a model of absorption by intestinal cells and showed a 
linear correlation between carotenoid uptake and lipophilicity (defined as their partition 
coefficient in 1-octanol/water).  Therefore, the uptake of the relatively lipophilic 
carotenes by Caco-2 cells is higher than that of the less lipophilic xanthophylls.  
Carotenoids that are more lipophilic can diffuse more easily through the membrane than 
the less lipophilic ones.  Provitamin A carotenoids, such as α-, and β-carotene and -
cryptoxanthin, are partly converted to vitamin A (primarily retinyl esters) in the intestinal 
mucosa cells.  Carotenoids and retinyl esters are incorporated into chylomicrons and 
secreted into lymph for delivery to the blood stream, where the chylomicrons are rapidly 
degraded by lipoprotein lipase [27]. The remaining chylomicron containing carotenoids 
are taken up by the liver, where they can be processed and secreted as a component of 
hepatic VLDL (very low-low density-lipoprotein), LDL (low density lipoproteins) and 
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HDL (high density lipoproteins). Carotenoids that are not filtered from circulation in the 
liver can be captured by extra-hepatic tissues before they are taken to the liver.  
1.7. Pro-vitamin A and non-pro-vitamin A carotenoids 
1.7.1. β-carotene, α-carotene, and β-cryptoxanthin (pro-vitamin A carotenoids) 
9 13
15
15'
13' 9'
HO  
Figure 12. Examples of provitamin A carotenoids 
 
In order to have pro-vitamin A activity, the carotenoid must have at least one 
unsubstituted β-ionone ring with methyl groups present in the correct numbers and 
positions on the polyene chain [29], see Figure 12.  The conversion of one mole of β-
carotene (two β-ionone rings in its structure, see Figure 12) theoretically gives two moles 
of retinal, while the conversion of one mole of β-cryptoxanthin, α-carotene, or γ-carotene 
(each one with one β-ionone ring) gives only one mole of retinal [29, 30].  Retinal is a 
β-carotene 
α-carotene 
β-cryptoxanthin 
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direct precursor of retinol (vitamin A) and retinoic acid. The conversion efficiency in vivo 
is much lower and the exact stoichiometry of the process is much debated. 
 
Figure 13. Central and eccentric cleavage of β-carotene (taken from Harrison [32]). 
 
-Cryptoxanthin is most prevalent in the diet as esters in fruits and vegetables. 
However these esters must be hydrolyzed to become bioavailable [30].  β-carotene is the 
most potent vitamin A precursor of all carotenoids; while α-carotene, β-cryptoxanthin, 
and γ-carotene show 30 to 50% of pro-vitamin A activity and 9-cis and 13-cis isomers of 
β-carotene less than 10%, compared to all-trans β-carotene [29].  The highest 
concentrations of vitamin A as pro-vitamin A carotenoids are found in carrots, sweet 
potatoes, pumpkin, kale, spinach, collards and squash, roughly 5–10 mg retinol activity 
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equivalents per 100 g (a retinol activity equivalent is equal to 1μg retinol or 12μg β-
carotene, or 24 μg of α-carotene or β-cryptoxanthin) [31].   
The conversion of pro-vitamin A carotenoids into vitamin A (retinoids) has been 
described to occur by two pathways: central and eccentric cleavage.  Both pathways are 
presented in Figure 8.  The principal pathway by which retinal is formed is that of central 
cleavage and β-carotene is converted to retinal by the cytosolic enzyme, β-carotene-
15,15′-oxygenase 1 (BCO1). BCO1 cleaves β-carotene at its central double bond (15,15′) 
to produce retinal.  For the enzymatic central cleavage two mechanisms have been 
proposed, one by a dioxygenase reaction and one by a monooxygenase reaction 
mechanism [29].  In the second pathway, eccentric cleavage occurs at double bonds other 
than the central 15,15′ double bond of the polyene chain. β-carotene can be cleaved to 
produce β-apo-carotenals having different chain lengths. The cleavage at the 9′,10′ 
double bond is catalyzed by β-carotene-9′,10′-oxygenase 2 (BCO2).  The two major sites 
of β-carotene conversion to vitamin A in humans are the intestine and liver.  In the 
intestine about half the dietary pro-vitamin A carotenoids are converted to retinol 
(presumably in the enterocyte, but possibly some conversion occurs in the lumen through 
the action of enzymes secreted in the bile) and about half are absorbed intact; however, 
the conversion varies between individuals [29]. 
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1.7.2 Lutein and Zeaxanthin (non-pro-vitamin A carotenoids) 
HO
OH
HO
OH
HO
OH
 
Figure 14. Major components of the macular pigment. 
 
Like the other carotenoids, lutein and zeaxanthin are found abundantly in nature.  
Humans obtain them only from their diet and they are most abundant in green leafy 
vegetables, fruits, and egg yolk.  These two yellow carotenoids are selectively 
accumulated in the macular area of the retina. They are also known as macular pigment 
carotenoids.   
The structural difference between lutein and zeaxanthin is found in a single end-
group (the ε-ring of lutein differs from the β-ring found in zeaxanthin). The configuration 
of the hydroxyl group in the - ring of zeaxanthin has a different stereo-chemical 
configuration than that in the -ring of lutein (see Figure 14).  Dietary lutein is 
metabolized to produce meso-zeaxanthin within the retina, although the exact mechanism 
remains unproven [32].  
lutein 
zeaxanthin 
meso-zeaxanthin 
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Figure 15. Spectra of lutein and zeaxanthin in ethanol[35]. 
 
Lutein and zeaxanthin are characterized by unique but similar UV-visible spectra 
(Figure 15).  The presence of two β-ionone end-group rings in the zeaxanthin structure 
extends the conjugation of the polyene chain and lowers the energy separation between 
the ground and excited state, shifting its absorption spectrum slightly to the red. Lutein 
absorbs light of slightly shorter wavelengths than zeaxanthin, (see figure 14).  
A. Lutein and zeaxanthin in visual development 
Bone and Landrum showed that the major components of the macular pigment were 
lutein, zeaxanthin, and meso-zeaxanthin [32].  The macula is a yellow region with 5-6 
mm of diameter (in adults) located in the posterior pole of the retina and it is unique to 
humans, see Figure 11.  Lutein and zeaxanthin are concentrated in the fovea, a depression 
located in the central macula coinciding with the position of maximum visual acuity.  
These carotenoids have also been detected in the lens and the ciliary body [33].  The 
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concentration of these carotenoids in the central retina approaches 1 mM, more than 
10,000 times the concentration in human serum or the liver [34].  The major roles of 
lutein and zeaxanthin in the eye are believed to be: enhancement of visual acuity by 
decreasing glare and chromatic aberrations; and protection against light-induced 
oxidative damage by filtering blue light incident on the retina and by scavenging ROS in 
the retina tissue [35]. 
 
Figure16.A) Human retina, taken from: http://www.gene.com/gene/products/education/tgr/eye-health-glossary.html. B) Frozen section through the fovea of a rhesus monkey, taken from the Snodderly Lab, http://www.sbs.utexas.edu/SnodderlyLab/galler. 
 
Studies have shown that lutein and zeaxanthin are present in prenatal eye as early 
as about 17 to 22 weeks of gestation, but there is no visible yellow spot (macula lutea) 
[36].  In the neonate human retina [37], lutein is the major carotenoid found in the central 
region, where the macula will develop, while in the fully developed retina zeaxanthin is 
the major carotenoid of the macula.  The foveal depression in the infant macula does not 
develop until approximately 16 weeks of age, and foveal cones (which are located in the 
center of the fovea) do not become fully mature until approximately 4 years of age.  
Cones are responsible for color vision and for high spatial acuity.  The transition to foveal 
A      B 
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zeaxanthin predominance occurs sometime before 3 years of age [38].  Studies in non-
human primates by Leung et al. [39] indicate that lifetime deprivation of dietary lutein 
and zeaxanthin and a low intake of n-3 fatty acids lead to changes in the fovea and retina 
damage, suggesting that both macular pigment carotenoids and n-3 fatty acids are 
essential for development and/or maintenance of the central retina.    
The retina is susceptible to oxidative stress because of the high concentrations of 
oxygen and the intensity of energetic short wavelength light.  Infant retinas may be more 
susceptible to light damage than adults because of the greater transmission of higher-
energy blue light through the infant's crystalline lens, which is not fully mature at birth 
[40].   
B. Lutein in neuro development 
 It has been reported that lutein is the predominant dietary carotenoid in human 
brain tissue in the infant [41, 42]. Studies of primates show that concentration of lutein in 
the retina is significantly related to the concentration lutein in the brain tissue [43].  Also, 
in adults it was shown that cognitive functions are related to macular pigment density and 
lutein supplementation is correlated with improved cognitive performance in a small 
study of elder subjects [44].  Leibelin-Boff et al.[42] found a correlation between lutein 
concentration and different fatty acids in the infant brain tissue; in addition, they found a 
positive correlation between amino acid neurotransmitters and lutein.  In other studies in 
mouse models, [45, 46] lutein was shown to have a protective role in neurons against 
oxidative stress.  These results suggest that lutein may be important in brain 
development. 
  
25  
In this introductory chapter, we have presented the biochemical foundation of 
carotenoids.  We have explained their most distinctive role in nature as antioxidants.  
Carotenoids are believed to be important as dietary micronutrients in humans since early 
life.  They have been most widely studied in relation to human nutrition and health 
because they have shown to be beneficial in decreasing the risk of degenerative diseases.  
The research presented in the following chapters studies the importance of 
carotenoids in early life.  We have studied the levels of carotenoids in human milk, 
maternal serum and cord blood in a group of Peruvian women to identify the variations in 
concentrations and to understand the influence and relationships in carotenoid transport 
from mother to child.  In addition we have studied the profile of fatty acids in human 
milk and the relationship between carotenoids and fatty acid composition in maternal 
milk. 
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CHAPTER II: Carotenoids in maternal serum and cord blood  
Dietary carotenoids have been extensively studied because of their association 
with health benefits.  The study and measurements of carotenoids in human serum and 
plasma have been of great interest to help evaluate patterns of consumption, 
bioavailability, and potential for impact on human health and nutrition [47].  As 
described in the previous chapter, humans absorb carotenes and xanthophylls from the 
diet. But mechanisms and regulation of metabolism, distribution, tissue uptake and 
deposition of carotenoids in tissues are still not fully understood.   
2.1. Background 
2.1.1. Analysis of carotenoids in human serum  
Khachik et al.[5] identified 34 different carotenoids, including 13 geometrical 
isomers, and 8 carotenoid metabolites in human plasma.  As a result of the many 
carotenoids found in the circulating system, carotenoids in plasma and serum have been 
study for dietary clinical and epidemiological interventions [48].  Various factors 
including total dietary intake, efficiency of carotenoid to release from the food matrix, the 
efficiency of their absorption and metabolism, and rate of tissue uptake all influence the 
levels of carotenoids in serum. From among all the various carotenoids found in food (50 
are commonly available in the human diet [49]), only six major carotenoids: β-carotene, 
α-carotene, lycopene, β-cryptoxanthin, lutein, and zeaxanthin are found in serum at levels 
higher than their metabolites or than other acyclic carotenes [5, 25].  As a consequence, 
these six carotenoids are the most studied and considered the most important carotenoids 
when evaluating human nutrition. 
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 High performance liquid chromatography (HPLC) has been the preferred method 
of analysis and isolation of carotenoids, and photodiode array detectors are the preferred 
detection method.  Carotenoids are ideal for detection of UV-Vis absorbance due to their 
conjugated double bond structure, and the PDA detection method has provided the 
absorption spectra to facilitate carotenoid identification [13, 48].  Reversed-phase 
separation systems are most commonly used, with C18 columns and C30 columns having 
been proven useful for the demanding separation of carotenoids required for the 
identification and quantification [13].  HPLC-NMR has, in certain instances, been a 
useful technique for elucidation of cis-trans isomers and it has been applied to the 
determination of stereoisomers of zeaxanthin and lutein in retina [50]. 
2.1.2. Carotenoids in maternal plasma and infant cord blood 
During pregnancy, carotenoids are transferred across the placenta to the fetus.  
Carotenoids are powerful antioxidants that can protect cells from oxidative stress. They 
are known to have an important role in human health and they are important in the diet 
during pregnancy and post-delivery, particularly -carotene, which serves as major 
source of vitamin A.  Oxidative stress has been suggested as a possible cause of human 
pregnancy-related disorders, such as preeclampsia [51].  Some studies found that women 
with preeclampsia generally have lower levels of β-carotene in plasma [52-54].  Although 
in a separate study conducted by Zhang et al. [51] this was not confirmed.  Nutritional 
and environmental factors are sources of oxidative stress and are suspected causes of 
preterm birth or low birth weight.  Premature birth and low birth weight are the most 
common cause of neonatal mortality [55].  There is no clear relationship between ROS 
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induced oxidative stress and pregnancy related disorders [56], but the available 
information suggests that antioxidants including carotenoids are important to maintaining 
a health of the mother during pregnancy and contribute to improved fetal nourishment.   
Therefore, research is important to determine the maternal antioxidant micronutrient 
requirements.  
Table 3. Studies showing carotenoid levels (µmol/L) in maternal plasma though pregnancy and cord blood of new born infants. 
 Yeum et al.[57] Oostenbrug et al.[58] Oostenbrug et al.[59] †Kiely et al.[60] Zhang et al.[51] 
1st trimester  
L=0.48±0.03 
β-C=0.30±0.02    
2nd trimester  
L=0.57±0.03 
β-C=0.27±0.02  
L+Z=0.46±0.20 
β-Cry=0.14±0.10 
β-C=0.23±0.10 
 
3rd trimester  
L=0.65±0.04 
β-C=0.24±0.02 
L=0.64±0.04 
β-C=0.25±0.03  
L=0.35±0.01 
Z=0.07±002 
β-Cry=0.43±0.03 
β-C=0.26±0.01 
Post-partum 
L=0.33±0.05 
Z=0.08±001 
β-Cry=0.59±0.12 
β-C=0.69±0.11 
L=0.64±0.04 
β-C=0.28±0.05 
L=0.65±0.04 
β-C=0.25±0.03   
Cord Blood 
L=0.05±0.01 
Z=0.01±0.00 
β-Cry=0.06±0.01 
β-C=0.03±0.01 
L=0.15±0.02 
β-C=0.03±0.00 
L=0.13±0.03 
β-C=0.03±0.00 
L+Z=0.13±0.10 
β-Cry=0.04±0.03 
β-C=0.04±0.03 
 
All values reported as mean ±S.E.M., except † mean ±s.d.   L=lutein, Z=zeaxanthin, β-C=β-carotene, β-Cry=β-cryptoxanthin.  Studies on β-carotene levels in cord blood have been reported [61-66], but there 
are only a few studies [57-60] that include lutein levels in addition to β-carotene in the 
new-born at time of birth.  These studies compared the carotenoid levels in mother’s 
plasma during pregnancy and postpartum with the levels found in cord blood in an effort 
to understand the maternal-fetal transfer of lipophilic molecules like carotenoids, retinol, 
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and vitamins A and E; in addition to assess their impact on pregnancy related disorders.   
An informative collection of data on cord blood and maternal carotenoid levels 
postpartum is shown in Table 3 (only studies including lutein were tabulated).  In Table 
3, we can see that carotenoid levels are lower in cord blood than in plasma.  Almost all of 
these studies found a correlation between maternal serum and cord blood for lutein, but 
only a few studies showed a correlation between maternal and cord blood for β-carotene 
and β-cryptoxanthin. 
Oostenbrug et al. [58] showed that lutein increased during pregnancy while β-
carotene decreased.  No significant change in the levels of carotenoids during the third 
trimester and post-partum was found by Oostenbrug.  Some of the studies reported lutein 
to be the carotenoid found in the highest concentration in serum and cord blood, although 
they did not analyze for all carotenoids. 
 The objective of our research described in this chapter was to determine 
carotenoid levels in mothers’ serum during post-partum and to correlate these levels with 
those in infants’ cord blood serum to understand if there is a selective mobilization from 
mothers to their infants.  Not many studies that address this question have been reported.  
Therefore, it is important to understand the role of carotenoids before and after delivery 
since they support the nutritional needs of the new born and contribute to optimal health 
in the mother.  We are especially interested in lutein and zeaxanthin because they appear 
to play a central role in the development of the healthy new-born retina. 
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2.2. Research Methods 
2.2.1. Study population 
The participants of the serum study were 74 Peruvian mothers and had a mean age 
was 26.3 years. All participants were in their first pregnancy and had no chronic health 
concerns.  All participants had a full-term pregnancy (the deliveries occurred after the full 
37 weeks of gestation).  The volunteers for the cord blood study were 26 Peruvian 
women who were also participants of the serum analysis study.  All volunteers were 
informed about the study and signed an IRB consent document (#040411).  
Anthropometric measurements were also collected to estimate body mass index (BMI).  
2.2.2. Sample collection  
Cord blood samples were collected from 26 volunteers. Cord blood was taken by 
a trained technician following clamping and cutting of the cord.  Blood was drawn from 
the umbilical vein using a vacutainer tube and was centrifuged to separate and collect the 
serum fraction. 
Maternal venous blood samples (10 mL) were collected during the 4th week after 
delivery from 74 volunteers. The drawn blood was then centrifuged to separate and 
collect the serum fraction. 
All serum samples were stored at -20°C for approximately one week at the study 
site.  Samples were transferred weekly for storage at -80°C until they were shipped 
overnight to our laboratory at Florida International University.  Samples were shipped 
frozen on dried ice. 
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2.2.3. Chemicals 
Ethyl alcohol USP grade, 1-pentanol 99%, hydrochloric acid, anhydrous diethyl 
ether, acetone, trimethylamine (TEA), anhydrous sodium sulfate, light petroleum ether, 
aluminum oxide powder (mesh 100, 99.9%), potassium hydroxide, and butylated hydroxy 
toluene, USP grade (BHT)  were all purchased from Sigma-Aldrich or Fisher Scientific. 
HPLC grade hexane, dichloromethane, methanol, and acetonitrile were purchased from 
Sigma-Aldrich and Fisher Scientific. Lutein, zeaxanthin standards were a gift from 
Industrial Organica S.A.  β-carotene standard was purchased from Sigma-Aldrich and the 
β-cryptoxanthin standard was extracted from red bell peppers.  
2.2.4. Instruments 
System I: High pressure liquid chromatography (HPLC) system equipment was used for 
standard purification and consisted of a Waters 2690 coupled to a photodiode array 
detector (PDA) Waters 996. A Cary 100 ultraviolet-visible (UV-vis) spectrophotometer 
was used to determine the concentration of the carotenoid internal standard.  
System II: The HPLC system used for carotenoid analysis was a Varian ProStar HPLC 
system with coupled to ProStar 335 photodiode array UV-visible detection system. A 
PhenomenexC-18 Ultracarb 3µm reversed-phase column was used with a mobile phase 
consisting of acetonitrile: methanol: triethylamine (85%: 15%: 0.1% v/v) and a flow rate 
of 1 mL/min with a detection at 450nm. Chromatographic data were analyzed using the 
Varian software package. 
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2.2.5. Preparation of Standards: 
A. Isolation of β-cryptoxanthin  
 β-Cryptoxanthin isomers were extracted from red bell peppers following the 
procedure used by Breithaupt and Bamedi [67].  The peppers were crushed using a 
blender followed by multiple extractions with diethyl ether/light petroleum ether (1:1 v/v) 
until the extracts had no color.  The extract were combined and dried over anhydrous 
sodium sulfate.  The resulting extract was dissolved in 200 mL of methanol, immediately 
after which 30 mL of methanolic KOH (30% w/v) was added. The hydroxide solution 
was neutralized and the carotenoids were extracted in dicholoromethane. The 
dichloromethane solution was washed three times with 100 mL of water, dried over 
anhydrous sodium sulfate and evaporated using a rotary evaporator.  The residue was 
dissolved in 3 mL of hexane in preparation for open column chromatography.  The glass 
column used was 400 mm long and alumina was used as the stationary phase. 1 mL of the 
extracted carotenoids was separated using the column with hexane as the mobile phase.  
After the collection of the first band (β-carotene), the mobile phase was changed to a 
mixture of hexane and acetone (9:1 v/v) to elute a second band which contained the β-
cryptoxanthin and its cis-isomers.   
B. Internal standard preparation: 
Monopentyl lutein ether (MPL) was used as an internal standard for this study.  
The standard was prepared by conversion of pure lutein to the desired compound by the 
following procedure. 5 mg of lutein was dissolved in 20 mL of 1-pentanol containing 1% 
v/v of concentrated hydrochloric acid. The reaction was stirred in the dark for 1.5 hours. 
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The resulting solution was extracted with a solution of dichloromethane. The product was 
concentrated and dissolved with ethanol prior to separation on reversed-phase HPLC. The 
monopentyl lutein ether component was collected from multiple injections, pooled and 
dried under N2. After reconstitution in acetonitrile the concentration of the resulting 
standard was determined using UV-visible spectrophotometry (ε=1.45x105 moleL-1 cm-1).  
2.2.6. Serum and cord blood carotenoid extractions and analysis: 
The serum samples from the subjects were stored in 2mL polypropylene vials, 
labeled, and stored at -80°C in the freezer before shipment to our laboratory.  The 
carotenoids were extracted according to a previous published technique [68]. Each 
sample was thawed at room temperature and vortexed briefly to ensure homogeneity. An 
aliquot of 400µL of serum was placed in a glass tube, 135ng-170ng of MPL was added, 
and 4 mL of a mixture of ethanol/deionized water (1:1) was added to the tube. The tube 
was vortexed for 30 seconds and carotenoids were extracted four times with 4 mL of 
hexane. For each extraction the tube was vortexed and centrifuged for 5 minutes. The top 
hexane layer was removed and combined in a 2 mL vial.  The resulting aliquot obtained 
was dried under nitrogen gas flow. The sample was re-dissolved in 80 µL of ethanol and 
transferred to a vial for HPLC injection. HPLC system I was used to separate and 
quantify the carotenoids in these samples. 
2.2.7. Statistical Analysis 
Data were analyzed using Statistical Packages for Social Sciences version 21.0 
(SPSS In c. Chicago, IL, USA).  Statistical methods were employed to test our 
  
34  
hypotheses; a two-way ANOVA test was conducted for a group of 26 subjects that 
donated milk samples during the three consecutive weeks of the study. 
2.3. Results 
2.3.1. Characterization of the standards 
The UV-Visible spectra shown in Figure 16 were obtained for the β-cryptoxanthin 
and standards prepared as described above.  The absorbance spectrum of the monomethyl 
lutein internal standard in Figure 17A  is the same as that of lutein (λmax: 445 nm and 474 
nm ).  The concentration of the standard was determined based on the absorbance at 
450nm,.  The spectrum in Figure 17B corresponds to β-cryptoxanthin isolated from red 
bell peppers, having λmax at 448 nm and 470 nm, consistent with the literature.(Citation-
Britton) 
 Figure 17. UV-visible spectra of standards used for analysis and identification.  A)Monopentyl lutein and B) β-cryptoxanthin. 
A 
 
 
 
 
 
 
 
B 
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Figure 18. Carotenoid standards’ chromatogram. 
 
 
Figure 19. Example of mother’s serum chromatogram 
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Figure 20. A typical chromatogram of the carotenoids extracted from cord blood. 
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Figure 18 shows a chromatogram of the combined carotenoids showing their a 
typical separation.   Figures 19 and 20 correspond to examples of serum and cord blood 
analyzed in the present study. 
Tables 4-5 show the results for all the samples analyzed to measure levels of 
carotenoids content in serum and cord blood.  Our data on carotenoid concentrations are 
consistent with previous reported values [51, 57, 69] 
 
Table 4. Results from the analysis of carotenoids in  cord blood for all subjects, amounts in µmol/L. 
Subject Lutein Zea β-cry L/Z Subject Lutein Zea β-cry L/Z 
N 26 26 18 26      
2701 0.08 0.04 0.04 2.12 2743 0.13 0.05 0.07 2.54 
2705 0.07 0.04 ** 2.01 4709 0.13 0.05 0.09 2.52 
2713 0.07 0.02 0.07 3.92 4712 0.06 0.04 0.05 1.39 
2716 0.09 0.04 0.13 2.00 4716 0.05 0.02 0.04 2.09 
2717 0.08 0.05 0.07 1.76 4718 0.02 0.02 ** 1.12 
2724 0.11 0.08 0.05 1.45 4725 0.05 0.02 0.06 2.00 
2727 0.08 0.04 0.04 1.70 4726 0.06 0.03 0.03 2.23 
2736 0.08 0.03 ** 2.93 4729 0.05 0.03 0.03 1.51 
2737 0.10 0.02 0.10 3.92 4730 0.04 0.02 ** 1.74 
2738 0.05 0.02 ** 3.15 4731 0.08 0.06 0.06 1.43 
2739 0.11 0.04 0.17 2.72 4738 0.04 0.02 ** 1.73 
2741 0.08 0.04 0.06 2.21 4739 0.07 0.05 0.62 1.46 
2742 0.06 0.03 ** 2.16 4741 0.07 0.04 ** 1.84  **not detected 
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Table 5. Results of analysis of carotenoids in mother’s serum for all subjects, amounts in µmol/L. 
Subject Lutein Zea β-cry β-car L/Z Subject Lutein Zea β-cry β-car L/Z N 74 74 74 61 74       
2701 0.47 0.09 0.15 ** 3.02 2741 0.30 0.14 0.46 0.17 2.19 
2702 0.17 0.07 0.09 ** 2.56 2742 0.21 0.08 0.23 ** 2.54 
2703 0.44 0.17 0.07 0.12 2.65 2743 0.41 0.12 0.67 0.24 3.53 
2704 0.55 0.16 0.38 ** 3.38 4701 0.28 0.12 0.13 0.18 2.33 
2705 0.37 0.15 0.19 ** 2.47 4702 0.35 0.16 0.12 0.13 2.21 
2706 0.19 0.11 0.40 0.07 1.81 4704 0.22 0.13 0.14 0.16 1.71 
2707 0.25 0.08 0.36 0.36 3.03 4705 0.21 0.08 0.15 0.12 2.65 
2708 0.22 0.10 0.23 0.10 2.31 4706 0.12 0.06 0.10 ** 2.04 
2709 0.20 0.09 0.46 0.13 2.22 4708 0.22 0.10 0.11 ** 2.33 
2710 0.48 0.15 0.13 0.19 3.25 4709 0.33 0.16 0.31 0.62 2.06 
2712 0.24 0.11 0.10 0.33 2.11 4710 0.23 0.07 0.08 0.45 3.33 
2713 0.26 0.10 0.29 ** 2.51 4712 0.15 0.08 0.23 0.20 1.84 
2714 0.16 0.09 0.26 0.36 1.87 4713 0.21 0.10 0.45 0.23 2.15 
2715 0.22 0.18 1.83 0.29 1.22 4714 0.24 0.08 0.20 0.56 3.06 
2716 0.17 0.06 0.43 0.23 3.00 4715 0.14 0.08 0.23 0.45 1.86 
2717 0.25 0.09 0.16 0.23 2.64 4716 0.33 0.18 1.30 0.29 1.84 
2718 0.18 0.09 0.29 0.15 2.05 4717 0.16 0.10 0.59 0.90 1.68 
2719 0.22 0.12 0.69 0.28 1.79 4718 0.13 0.05 0.18 0.23 2.67 
2720 0.25 0.10 0.32 0.51 2.57 4719 0.13 0.09 0.09 0.21 1.51 
2721 0.16 0.05 0.22 ** 2.90 4720 0.20 0.10 0.15 0.17 2.01 
2722 0.21 0.12 0.51 0.36 1.82 4721 0.12 0.08 0.75 0.00 1.55 
2723 0.46 0.14 0.44 1.10 3.22 4723 0.28 0.12 0.63 0.37 2.30 
2724 0.20 0.06 0.29 0.16 3.24 4724 0.19 0.09 0.53 0.20 2.24 
2725 0.24 0.07 0.30 0.24 3.30 4725 0.40 0.12 0.88 0.36 3.32 
2726 0.69 0.26 0.99 0.21 2.65 4726 0.32 0.12 0.55 ** 2.66 
2727 0.29 0.10 0.48 0.19 2.97 4727 0.41 0.16 0.58 0.05 2.50 
2728 0.30 0.13 0.79 0.15 2.34 4728 0.31 0.13 0.66 0.26 2.44 
2729 0.39 0.17 0.28 ** 2.23 4729 0.17 0.08 0.46 0.28 2.03 
2730 0.65 0.27 0.46 0.27 2.43 4730 0.24 0.08 0.09 ** 3.16 
2732 0.16 0.07 0.21 0.14 2.34 4731 0.36 0.17 0.85 0.21 2.07 
2733 0.24 0.05 0.12 ** 5.00 4732 0.23 0.10 0.32 0.17 2.36 
2735 0.40 0.17 1.31 0.43 2.35 4733 0.12 0.05 0.23 0.17 2.35 
2736 0.25 0.14 0.25 0.23 1.85 4736 0.36 0.08 0.13 0.12 4.57 
2737 0.33 0.13 0.44 0.31 2.55 4738 0.14 0.07 0.22 0.13 2.14 
2738 0.34 0.19 0.36 0.14 1.79 4739 0.16 0.08 0.45 0.16 1.87 
2739 0.34 0.13 0.57 0.41 2.64 4740 0.30 0.12 0.22 0.18 2.58 
2740 0.37 0.13 0.72 0.12 2.79 4741 0.29 0.13 0.32 0.27 2.19 
**not detected 
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In maternal serum, β-carotene was detected in the majority of the subjects (81%), 
however in cord blood, β-carotene was either not detected or barely detected, therefore 
we chose to not to include β-carotene in the results for cord blood.  β-cryptoxanthin was 
detected in cord blood in 69% of the subjects as well as in all maternal serum samples.  
Table 6 shows the correlations found in serum for lutein, zeaxanthin, and β-
cryptoxanthin; β-carotene did not show any significant correlation with the rest of the 
carotenoids.  In cord blood, only lutein and zeaxanthin correlate; β-cryptoxanthin did not 
correlate with either lutein or zeaxanthin. 
Table 6. Correlations (r) of carotenoids in serum 
N=74 lutein zeaxanthin β -cryptoxanthin 
lutein -- 0.81** 0.25* 
zeaxanthin 0.81** -- 0.48** 
cryptoxanthin 0.25* 0.48** -- 
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). 
 Figure 21. Correlation of lutein in maternal serum and cord blood (r=0.395, p=0.046, α=0.05) 
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Figure 22 Correlation of lutein and zeaxanthin in (A) cord blood (r=0.69, p<0.001) (B) maternal serum (r=0.81, p<0.001, α=0.05). 
Figure 23 Correlation of BMI to maternal serum of (A) β-cryptoxanthin (r= -0.28, p=0.02) (B) β-carotene (r = -0.26, p=0.055, α=0.05). 
 
Figures 21-23 show the different correlations found for carotenoids in maternal 
serum and cord blood.  Only lutein shows a correlation between cord blood and maternal 
serum (r=0.395, p=0.046, N=26), Figure 21, while zeaxanthin and β-cryptoxanthin did 
not.  Table 7 shows the correlations found between BMI and pro-vitamin A carotenoids, 
lutein and zeaxanthin did not correlate with BMI. 
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Table 7. Correlation between BMI and pro-vitamin A carotenoids in maternal serum. 
 β-cryptoxanthin N=69 β-carotene N=56 
BMI r= -0.272  p=0.024 r= -0.258 p=0.055 
 
Table 8. Lutein and zeaxanthin concentrations (µmol/L) in cord blood according to newborn’s sex. 
Female 
N=15 
Male 
N=10 
Lutein 0.07 ± 0.02 0.07 ± 0.03 
Zeaxanthin 0.04 ± 0.01 0.03 ± 0.01 
 
 After dividing the cord blood data by newborn’s sex (Table 8), we did not observe 
any significant difference for the levels of lutein or carotenoids between the groups.  
 
2.4. Discussion and Conclusions 
 Our study measured the carotenoid levels in cord blood and in maternal serum 
during the first month post-partum and investigated the relationships between these 
values. Tables 9 and 10 summarize these data averaged for all samples.  Our results are 
within the ranges reported by previous investigations, see Table 2.  The only study of 
Peruvian women’s serum was reported by Zhang et al. [51] during the third trimester of 
gestation.  The carotenoids levels in that study were reported to be L=0.35±0.01, Z=0.07
±002, β-Cry=0.43±0.03, and β-C=0.26±0.01. The values reported here (see Table 9) 
for lutein and β-cryptoxanthin are lower in comparison.  It should be recognized that our 
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results were taken during the 4th week post-partum, which could affect the levels 
reflected in serum attributable to micronutrients transfer to milk during the lactation 
period.  In addition, the dietary intake that varies by subject will change the concentration 
of carotenoids in maternal serum, and our data are from a smaller sample than in the 
study by Zhang. 
Table 9. Average carotenoids levels (µmol/L) in mother’s serum. 
Mothers’ serum 
  N Min Max Mean Std. Dev. Median 
Lutein 74 0.12 0.69 0.27 0.12 0.24 
Zeaxanthin 74 0.05 0.27 0.11 0.04 0.10 
β-cryptoxanthin 74 0.07 1.82 0.40 0.32 0.30 
β-carotene 60 0.05 1.10 0.27 0.18 0.21 
L/Z 74 1.22 5.00 2.47 0.64 2.35 
BMI 69 19.61 41.89 27.94 4.00 27.74 
  Table 10. Average carotenoids levels (µmol/L) in cord blood. 
Cord Blood 
  N Min Max Mean Std. Dev. Median 
Lutein 26 0.02 0.13 0.07 0.03 0.07 
Zeaxanthin 26 0.02 0.08 0.04 0.01 0.04 
β-cryptoxanthin 18 0.03 0.61 0.10 0.13 0.06 
L/Z 26 1.12 3.92 2.14 0.72 2.01 
 
As anticipated based on previous reports [57, 60], for the paired results (see Table 
11), comparing cord blood to maternal serum shows that carotenoid concentrations are 
significantly lower (p<0.001) in cord blood than in maternal serum for lutein, zeaxanthin, 
and β-cryptoxanthin.  In cord blood, the levels of lutein, zeaxanthin, and β-cryptoxanthin 
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were found on average to be 26.3%, 32.1%, and 19.5% that of maternal serum.  Lutein 
was the most abundant carotenoid found in cord blood in more than 87% of the cases, but 
in maternal serum β-cryptoxanthin was the most abundant carotenoid in 60% of the cases.  
Similar results were observed by Yeum et al. [57] in their study.  We found that β-
carotene levels are barely detected in cord blood; other investigators have found low 
levels of β-carotene in cord blood.  It has been proposed by Dimenstein et al. [64] that 
this may reflect enhanced metabolism of β-carotene by the embryo or reduced placental 
transport of β-carotene in comparison to other carotenoids.  A comparison of the ratio of 
lutein to zeaxanthin in cord blood (L: Z= 2.14 ± 0.72) to that in maternal serum (L: Z = 
2.49 ± 0.52) does not show any statistically significant variation. On this basis we 
conclude that lutein is not preferably uptake by the cord blood or actively transported to 
the fetus during the gestation period. 
Table 11. Carotenoid concentrations (µmol/L) for maternal and cord blood in paired samples. 
 N Cord blood Maternal Serum Lutein 26 0.07 ± 0.03* 0.28 ± 0.09 
Zeaxanthin 26 0.04 ± 0.01* 0.11 ± 0.04 
β-cryptoxanthin 18 0.10 ± 0.13* 0.50 ± 0.29 
L/Z 26 2.14 ± 0.72 2.49 ± 0.52 
*significantly different (p<0.001) 
There was a significant correlation of lutein (r=0.41, p=0.04) between serum and 
cord blood, see Figure 20.  This correlation has been reported before, while the 
correlation between other carotenoids, such as zeaxanthin and pro-vitamin A carotenoids, 
has not been consistently reported.  In addition, lutein correlates highly with zeaxanthin 
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in both serum (r=0.81, p<0.001) and cord blood (r=0.69, p<0.001), see Figure 22, 
whereas β-cryptoxanthin is correlated with lutein (r=0.25, p=0.03) and zeaxanthin 
(r=0.48, p<0.001) only in serum and not in cord blood.   
It was also observed that in maternal serum, β-carotene concentrations do not 
correlate with any other carotenoid measured in the study.  Interestingly in maternal 
serum, body mass index was found to inversely associate with pro-vitamin A carotenoids, 
β-cryptoxanthin (r = -0.28, p = 0.02), and β-carotene (r = -0.26, p = 0.055), see Table 7 
and Figure 23, but did not correlate with lutein or zeaxanthin.  A number of other 
investigations [70-72] have also found an inverse association between BMI and 
carotenoid concentrations in serum. In all of the cases, β-carotene was found to be 
correlated with BMI.  Andersen et al.[71] have suggested that this relationship, between 
BMI and carotenoids, may be explained by three factors.  First, the correlations could 
reflect dietary and lifestyle factors that are particular to each individual.  Second, since 
carotenoids are lipophilic, they are distributed between blood and fat tissue. Thus, 
carotenoids are lower in individuals with higher BMI because a relatively larger 
proportion is solubilized in adipose.  A third possible explanation is that individuals with 
more adipose tissue may experience greater oxidative stress, leading to degradation of 
carotenoids at a greater rate.  In addition, β-carotene conversion to vitamin A depends on 
several factors, one which is BMI [73].  This relationship is established by adipose tissue 
being a site of β-carotene accumulation and BCMO1 expression.  Therefore, the inverse 
relationship between β-carotene and BMI could reflect the partition of pro-vitamin A 
carotenoids between plasma and adipose tissue.  Because of these factors, the 
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concentration of β-carotene is greater in serum when BMI is low, but with a higher BMI 
it would be concentrated primarily within the adipose tissue.  We cannot say the same 
about β-cryptoxanthin because the conversion of β-cryptoxanthin to vitamin A is lower; 
thus additional studies are needed to address this finding.  Lastly, in this study we did not 
find the lutein levels in cord blood to be sex dependent as suggested in a previous 
investigation [74] of lutein levels in cord blood. 
 In conclusion, this is the first time levels and relationships of carotenoids between 
mothers and new-born were study in this particular population.  Our study found an 
inverse correlation between BMI and β-cryptoxanthin in maternal serum.  It is 
informative to address the carotenoid maternal nutrition status in Peruvian women.  
Carotenoids in cord blood are lower in concentration than those in maternal serum.  
Lutein was also found to be a major component in both maternal serum and cord blood.  
Lutein showed a positive correlation between maternal serum and cord blood, and the 
ratio of lutein to zeaxanthin was similar in both.  One possible explanation for this result 
could be that the levels in maternal serum measured were depleted because of the 
preferential transfer of this nutrient to breast milk to maintain the nourishment required 
by the infant during the same period.   Consequently, we cannot confirm that placental 
lutein transfer is favored during early life.  More research is needed to help understand 
this relationship.   
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CHAPTER III: Fatty acids in human milk  
Human milk is the sole source of nutrition for infants for the first six months of 
life.  Milk is a complex fluid that contains carbohydrates, salts in solution, milk proteins 
(casein) in colloidal dispersion, cells, cellular debris, and lipids, mostly in emulsified 
globules [75]. It also contains biological components such as antibodies, enzymes, and 
hormones that contribute to the development of the digestive tract and the immune 
system in the new born [76].  Macronutrients such as proteins, fat, and carbohydrates, are 
the major components present in human milk while micronutrients comprise less than 
0.5% (vitamins, carotenoids, retinol, and some minerals).   
 
Table 12. Multiple functions of the major nutrients of human milk (adapted from [77] p. 70). LC-PUFA = long chain polyunsaturated fatty acids; FFA = free fatty acids, produced from triglycerides during fat digestion in the stomach and intestine. 
Macronutrients  Amount Function 
 sIgA 50-100 mg/dL Immune protection  IgM 2 mg/dL Immune protection Protein IgG 1 mg/dL Immune protection  Lactoferrin 100-300 mg/dL Anti-infective, iron carrier  Lysozyme 5 - 25 mg/dL Anti-infective  α-Lactalbumin 200-300 mg/dL Ion carrier (Ca+) part of lactose synthase  Casein 200-300 mg/dL Ion carrier, inhibits microbial adhesion to mucosal membranes 
     Lactose 6.5-7.3 g/L Energy source Carbohydrate Oligosaccharides 1.0-1.5 g/L Microbial ligands  Glycoconjugates  - Microbial and viral ligands 
     Triglyceride 3.0-4.5 g/L Energy source Fat LC-PUFA  Essential for brain and retinal development and for infant growth  FFA  Anti-infective Fat  
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The lipids present in human milk comprise ~3–5% by mass and occur principally 
as globules emulsified in the aqueous phase (87%) of the fluid. Lipids are present as 
triacylglycerols (TG) (~98%), phospholipids (~0.8%), and cholesterol (~0.5%) [77].   
This chapter provides an overview of the general concepts of fatty acids and on 
fatty acids in human milk and includes our results of the analysis of human milk fat in 74 
Peruvian women.  The data include measurement of the amounts of fatty acids from the 
triglycerides present in milk.  A discussion of the influence of the mother’s diet on the 
fatty acid profiles of human milk is also included.  
 
3.1. Background  
3.1.1. Fatty acid structure and functions 
  Fatty acids are hydrocarbons composed of four to thirty six carbon atoms with a 
methyl group at the (omega, ω) end of the molecule and a carboxyl group at the other 
end.  The carbon chain can be short (2-4 carbons), medium (6-12 carbons), long (14-18 
carbons), or very long (derived from 18 carbon or more) [78].  In naming, the carbon 
atom adjacent to the carboxyl group is designated as the α carbon, and the following 
carbons in the chain are labeled sequentially with the Greek letters β, γ, δ, etc.  The Latin 
letter “n” is regularly used, instead of the Greek ω, when indicating the position of any 
double bonds as counted from the methyl end, see Figure 1.  The nomenclature also 
allows the location of double bonds to be referenced to the carboxyl group [79].  A short 
formula that is conventionally used to designate the identity of fatty acids.  In the short 
formula the carbon number is followed by the number of double bonds present and the 
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location of the double bonds is assigned relative to the ω carbon atom.  For example, in 
linoleic acid which has 18 carbon atoms and two double bonds the final double bond is in 
the omega-6 (n-6) position and the fatty acid is designated 18:2n-6.   
 
Figure 24. The structure of linoleic acid (LA), short formula 18:2n-6. 
For our purposes and based on the extent of unsaturation, fatty acids can be 
grouped in three categories: saturated, monounsaturated and polyunsaturated.  More than 
20 different fatty acids are found in foods like fruits, vegetable oils, seeds, nuts, milk, 
animal fats, and fish oils.  Essential fatty acids, such as ω-3 fatty acids (those  in which 
the double bonds are located starting at the third carbon from the methyl end-group), 
have important cellular functions and are required in the human diet because there is no 
biochemical pathway capable of producing these molecules in the body [80].  
 
A. Saturated fatty acids (SFA) 
Saturated fatty acids (SFA) have only a single carbon-carbon bond; therefore they 
contain the maximum number of hydrogen atoms attached to every carbon atom.  Most 
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SFAs are straight hydrocarbon chains with an even number of carbon atoms. The most 
common fatty acids contain 12–22 carbon atoms.  Some particularly representative 
examples of SFAs are palmitic acid (C16:0), stearic acid (C18:0), and myristic acid 
(C14:0).  Consumption of saturated fatty acids increases low-density lipoprotein 
cholesterol levels and it has also been associated with an increased risk of coronary heart 
disease [81, 82].  However, new studies on cellular and physiological functions of 
individual SFAs emphasizes that short and medium chain SFAs, and myristic acid 
(C14:0) have important cellular and metabolic roles [83]. 
 
O
OH 
Figure 25. The structure of a saturated fatty acid, stearic acid (18:0). 
 
B. Monounsaturated fatty acids (MUFA) 
Monounsaturated fatty acids (MUFA) have one carbon–carbon double bond that 
can be located in several different positions relative to the methyl-end group.  The 
orientation of the hydrogen atoms around the double bond determines the geometric 
configuration.  In a cis (Z) configuration, the hydrogen atoms are present on the same 
side of the double bond, while in the trans (E) configuration, they are on opposite sides.  
The most common naturally occurring MUFAs have a chain length of 16 –22 carbon 
atoms and a double bond having a cis geometry. Oleic acid (cis C18:1n-9) comprises 
about 92% of cis MUFAs in the human diet [84]. The other common MUFAS are cis-
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palmitoleic acid (cis 16:1n-7), and cis-vaccenic acid (cis 18:1n-7).  Studies have found 
that an increased intake of monounsaturated fatty acids correlates with a decreased risk of 
coronary heart disease [80, 84].  Geometrical isomerism (cis/trans isomerism) modulates 
the shape and physical properties of the molecule; cis fatty acids have a ‘kink’ in the 
chain whereas trans fatty acids (TFA) are ‘straight’ and function comparably to SFA 
[85].  The cis fatty acids are thermodynamically less stable than the trans form.  They 
have lower melting points and are consequently often liquids at room temperature [86].   
O
OH
O
OH
9
 
 
Figure 26. The structures of the monounsaturated fatty acids of oleic acid (18:1n-9) (a) the trans structure, elaidic acid and (b) the naturally occurring cis structure. 
 
C. Polyunsaturated fatty acids (PUFA) 
Polyunsaturated fatty acids (PUFA) have two or more carbon-carbon double 
bonds.  If the first double bond is found between the third and the fourth carbon atom 
from the ω carbon, these are called ω-3 or n-3 fatty acids.  If the first double bond is 
between the sixth and seventh carbon atom, then they are called ω-6 or n-6 fatty acids. 
(a) 
 
 
 
(b) 
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The double bonds in PUFAs are usually unconjugated and frequently separated from each 
other by a methylene group [79].  
Humans acquire PUFAs from their diet.  They are metabolized in the body by 
elongation (adding carbon atoms) or by further desaturation (extraction of hydrogen 
atoms).  Desaturases are capable of forming new double bonds between carbon atoms 
found between an existing double bond and the carboxyl group.  Linoleic acid (LA or 
18:2n-6) and α-linolenic acid (ALA or 18:3n-3) are the principal essential PUFAs.   LA 
and ALA are the precursors of arachidonic acid (20:4n-6), eicosapentaenoic acid (EPA; 
20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), respectively.  A beneficial effect on 
the cognitive development of infants and children is attributed to dietary supplementation 
during pregnancy and lactation with n-3 fatty acids [80]. 
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Figure 27. The structures of polyunsaturated fatty acid, (a) α-linolenic acid (ALA, 18:3n-3), (b) eicosapentaenoic acid (EPA, 20:5n-3), and (c) docosahexaenoic acid (DHA, 22:6n-3). 
(a) 
 
(b) 
 
(c) 
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3.2. Lipids in Human Milk 
3.2.1 Milk fat globules 
Human milk fat globules are the lipid delivery carriers secreted by the mother for 
nutritional purposes.  They provide 40 - 55% of the total energy intake for infants [87].  
The milk fat globule is formed by a unique mechanism that provides a specific 
composition and structure [88].  The fat globules in human milk are typically about 1 to 
10 µm in diameter.  Most of them (70-90%) are about 1µm but most of the lipid mass is 
contained in those that are about 4 µm.  The large surface area of these globules, 
particularly the smaller globules, can bind many lipase enzymes that will contribute to 
triglyceride digestion [89].  The core of the globules is mainly composed of 
triacylglycerols and nonpolar lipids such as cholesteryl and retinyl esters. The outer 
surface of fat globules consists of bipolar components such as phospholipids, proteins, 
mucopolysaccharides, cholesterol, and enzymes [75].  The thin phospholipid layer is 
commonly referred as the milk fat globule membrane.  Milk lipids must be liquid in order 
to form microdroplets within the secreting cells and they will fuse into droplets that will 
finally be secreted as globules [75].  Studies have reported that the polar lipids in the milk 
fat globule membrane have different benefits for human health as a result of their 
involvement in cell functions such as growth, development, and transport systems [87].   
3.2.2 Origins of milk fat  
Mammary alveolar cells are stimulated to produce milk fat by prolactin secreted 
from the anterior lobe of the pituitary gland and by emptying of the breast after lactation 
[89].   Fatty acids in milk can come from the uptake from circulation or from de novo 
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synthesis within the mammary epithelial cells. Although many fatty acids are of dietary 
origin others are formed by metabolism of dietary fatty acids in the maternal liver [90].  
Short-chain fatty acids (4 to 8 carbons) and medium-chain fatty acids (10 to 14 carbons) 
are produced almost exclusively from de novo synthesis [91].  Fatty acids with 16 
carbons come from either de novo synthesis or from the uptake, while long-chain fatty 
acids (>16 carbons) are derived exclusively from the uptake of circulating lipids derived 
from dietary intake.  Preformed fatty acids are taken up from circulating lipoproteins by 
the mammary gland and may be used as the building blocks for further synthesis of the 
fats that ultimately comprise milk fat.  Non-esterified fatty acids originate from the 
absorption of lipids from the digestive tract and from the mobilization of body fat 
reserves [91].   
Table 13. Factors associated with changes in the total lipid content of human milk (adapted from [75] p. 1254) 
Factor Effect 
Duration of a nursing or feeding Increase 
Age postpartum, stage of lactation Increase 
Diurnal rhythm Variable (related to time of samples and maternal 
meals) 
Between breast Occurs 
Gestational age at birth (pretermn vs. term) Occurs 
Diet regionality May Occur 
Nutrition status Decrease in malnourished women 
High carbohydrate, low fat diet May decrease 
Infections, metabolic disorders Usually decreases 
Parity Decrease 
Season Related to diet and regionality 
Individuality Adiposity increases 
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The volume of human milk produced by each mother as well as macronutrients 
and micronutrients varies among individuals.   The composition of human milk is 
influenced by genetics, nutrition, and other factors.  In Table 13, a list of factors that have 
been observed to influence the fat content in human milk and their effects is presented 
[75].  As seen in Table 13, the lipid content in human milk can be influenced by different 
factors like diet, duration of nursing, and parity. 
3.2.3. Lipids in human milk 
Triacylglycerols (TG) are the main component of the lipids in milk accounting for 
more than 98% of the total fat.  Phospholipids and cholesterol contribute about 0.7% and 
0.5% of milk, respectively [77, 89].  The TG structure controls the liquidity of the lipid 
globules and the identity of the products formed by the lipolysis reactions in the stomach 
and intestine [75].  Table 14 shows data taken from a study [92] of the composition of 
milk in full- and pre-term mothers.  From this Table, we can compare the changes 
between the first and the 12th week of lactation.  As seen in Table 14, the percent total 
lipid in milk increases with time as well as the amount of triacylglycerols.   
 
Table 14. Lipid class composition during lactation (adapted from [92]). Amounts in wt %, total lipid % in mean ± SEM. 
 Percentage of total lipids at different lactation days days 3 7 21 42 84 
n 39 41 25 18 8 
Total lipid % in milk 2.04 ± 1.32 2.89 ± 0.31 3.45 ± 0.37 3.19 ± 0.43 4.87 ± 0.62 Phospholipid 1.1 0.8 0.8 0.6 0.6 Cholesterol 1.3 0.7 0.5 0.5 0.4 Triacylglycerol 97.6 98.5 98.7 98.9 99.0 Cholesteryl esters (mg/dL) 5 1 1 1 1  
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 Figure 28. The stereospecific number of the substitution of fatty acids in triacylglycerols. 
 
Human milk usually contains seven major fatty acids in amounts higher than 1%.  
TG vary in the kinds and amounts of fatty acids present in their structure.  In the TG 
structure, three positions are available for different types of fatty acids (see Figure 15) 
and the distribution of fatty acids is not random.  The stereospecific numbering (sn) 
designates the location of fatty acids within the triglyceride molecule (see Table 16).  The 
distribution of fatty acids between the outer positions (1 and 3, referred as sn-1 and sn-3, 
see Figure 15) and the inner position, sn-2, in the molecule directs the partition between 
the free and the 2-monoacyl-sn-glycerol forms. The TG substitution pattern consequently 
modifies the rate of intestinal fatty acid uptake by the body [93].  Therefore, the pattern 
of fatty acids substitution in TG and their prevalence are unique variables and in different 
studies [93, 94] it has been shown that palmitic acid is favorably located on the sn-2 
position.  Presence of palmitic acid in this location improves the absorption of fat and 
calcium in the small intestine of infants [75].  The other two major fatty acids in human 
milk, oleic and linoleic acids, are predominantly esterified at the sn-1 and sn-3 positions 
sn-1 
sn-2 
sn-3 
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[94].  Human milk differs from infant formulas in fatty acid composition and their 
positional distribution.  Studies have shown human milk fat to be better absorbed in 
premature and newborn infants because the TG structure influences the way fatty acids 
are metabolized and incorporated as nutrients [95]. 
Milk phospholipids comprise on average about 0.6% of total fat in milk.  The 
major classes of phospholipids are phosphatidyl choline (28.4%), phosphatidyl 
ethanolamine (27.7%), phosphatidyl serine (8.8%), phosphatidyl inositol (6.1%), and 
sphingomyelin (37.5%). Phospholipids contribute functionally to maintaining the 
emulsion of fat globules.  Human milk has high cholesterol content and cholesterol is the 
major milk sterol contributing 90.1% of the total sterol content, followed by desmosterol 
(8.6% of total sterols).  The maternal diet has no appreciable effect on milk cholesterol 
and breastfed infants have a relatively large cholesterol intake, about 25 mg/kg body 
weight, (relative to adults). A result of this is that plasma cholesterol values are higher in 
breastfed than in formula-fed infants [89]. 
 
Table 15. Distribution (%) of essential fatty acids in the glycerol structure in colostrum and mature milk (adapted from [96] p. 270). LA = linoleic acid, ALA = α-linoleic acid, AA = arachidonic acid, DHA = docosahexaenoic acid. 
stereospecific numbering position Colostrum Mature milk LA % ALA % AA % DHA % LA % ALA % AA % DHA % sn-1 35 33 10 8 37 29 6 0 sn-2 22 18 45 50 21 26 49 67 sn-3 43 49 45 42 42 45 45 33  
In humans, glucose-derived acetyl-CoA is the major source of C2 units for fatty 
acid synthesis, and the maternal dietary intake of polyunsaturated fatty acids (PUFA) is a 
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major contribution to the amounts of n-6 and n-3 fatty acids secreted into mother’s milk 
[96].  The long-chain saturated fatty acids, cis-monounsaturated fatty acids, trans-fatty 
acids and n-6 and n-3 PUFA are taken up by the mammary gland from circulation and 
then acylated into PUFAs for secretion in milk. Mammary gland-specific acyl 
transferases preferentially esterify 16:0 and 18:0 PUFAs at the center sn-2 position in the 
formation of TG, rather than at the sn-1 or sn-3 positions, as in other tissues [96].  
 
 
Figure 29. Metabolic conversion of linoleic acid (n-6 series) and α-linolenic acid (n-3 series) to form the long-chain polyunsaturated fatty acids (adapted from [97] p. 7). 
 
Humans cannot synthesize essential n-3 and n-6 PUFAs.  The parent fatty acids of 
these families, α-linolenic acid (C18:3n-3, ALA) and linoleic acid (C18:2n-6, LA) are 
essential fatty acids and are required in the daily diet since they cannot be formed by the 
mammalian cells.  ALA and LA are converted to more highly unsaturated fatty acids and 
to longer chain fatty acids, through enzymatic chain elongation and desaturation.  LA and 
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ALA are obtained from the diet in high amounts from plant, seed, and nut oils; LA and 
ALA amounts vary among different types of cooking oils.  ALA is sequentially elongated 
and desatured to eicosapentaenoic acid (C20:5n-3, EPA) and then to docosahexaenoic 
acid (C22:6n-3, DHA).  LA is elongated and desaturated to arachidonic acid (C20:4n-6, 
AA).  DHA is an especially important and major component of cell membranes in the 
brain and the retina.  AA is also a membrane component and it is a precursor to the potent 
signaling molecules, the prostaglandins and leukotrienes [97].   
The pathway for conversion of essential fatty acids to AA and DHA is shown in 
Figure 29. Both n-3 and n-6 PUFAs are substrates of the same chain 
elongation/desaturation enzymes, and consequently there is a competition between them 
for the enzyme [97].  Therefore, the balance between LA and ALA in the diet is very 
important.  The significance of this competition is that an excessive amount of n-6 can 
reduce the production of DHA and EPA, which is needed for optimal neural 
development.  Moreover, excessive production of AA can lead to imbalances 
contributing to prostagland and leukotrin production leading to pro-inflammatory 
conditions [98].   
Low rates of DHA synthesis from ALA appear to be a general characteristic of 
human metabolism, with the slowest step in (n-3) fatty acid desaturation being the 
conversion of EPA to DHA [99].  It has been observed that dietary DHA is well absorbed 
and readily incorporated into plasma and blood cell lipids in humans.  Animal studies 
have also shown that dietary DHA is readily incorporated into lipids of the developing 
brain before and after birth [99].  As mentioned earlier, DHA is particularly important in 
the central nervous and visual system.  In the brain, DHA is enriched in synaptic terminal 
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membranes, has diverse roles in brain growth and function, and protects against oxidative 
stress [99].  High concentrations of DHA are present in phosphatidylserine and the 
ethanolamine phosphoacylglycerols (ethanolamine plasmalogen and 
phosphatidylethanolamine) of brain grey matter and the outer segments of rod and cone 
photoreceptors in the retina DHA comprises ≤ 80% of the PUFA in the retina outer 
segment disks.  Phospholipids present in both fatty acids are DHA [96].  A study by Niu 
et al. [100] has shown that low levels of DHA caused by n-3 FA deficiency leads to 
suboptimal function in learning, memory, olfactory-based discrimination, spatial 
learning, and visual acuity.   
TFA are trans isomers of unsaturated fatty acids which can also be found in 
human milk.  TFA originate from the maternal diet because humans cannot synthesize 
them.  They are formed from ruminant fats by hydrogenation and from biohydrogenation 
of dairy foods. Trans isomers can also be formed from the partial hydrogenation of 
vegetable oils [101].  Margarine, frying fats, and baking shortenings may contained up to 
40-50% TFA while ruminant fats contain 1-8% [102].  High intakes of TFA have shown 
to have a correlation with an increased risk of coronary heart disease, but when the data 
were evaluated, moderate intakes were not associated with increased risk [103].  As 
mentioned earlier in this review, a mayor difference of TFA and cis-fatty acids is their 
melting points. The melting point of oleic acid (cis C18:1) is 10-11°C, while the melting 
point of elaidic acid (trans C18:1) is 44.5-45.5°C. The trans isomer is also better-
absorbed and incorporated into tissue lipids than its corresponding cis fatty acids [75]. 
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3.2.4. Review of Previous Studies 
Over the past few decades, studies on the composition of human milk fatty acids 
in women from different countries around the world have presented the variation in the 
amounts of fatty acids among diverse populations.  In order to better understand this 
variability we chose to study a population that has not been previously studied, in this 
case a Peruvian population. 
 Table 16. List of studies grouped according to their geographic location, country and first author of the citation. 
Europe North America South America Africa Oceania Asia South Asia Middle east 
UK, Yuhas [104] Canada, Yuhas[104] Chile, Yuhas[104] 
Nigeria (urban), Glew[105] 
Australia, Yuhas[104]  
China, Yuhas[104] Phillipines, Yuhas[104] 
West Iran, Bahrami [106] 
Sweden, Xiang[107] US, Yuhas[104] Argentina, Marin[108] 
Nigeria (rural), Glew[105] 
Australia, Makrides [109] 
North China, Wan[110] West India, Roy[111] 
Iraq, Al-Tamer [112] 
Germany, Genzel-Boroviczeny[113] Mexico, Yuhas[104] Bolivia, Martin[114] 
Mauritius, Pugo-Gunsan[115]  
Japan, Yuhas[104] 
Nepal, Schmeits [116] 
Israel, Saphier [117] 
Spain, Lopez-Lopez[94]  
Brazil, Nishimura [118]     
Turkey, Aydin [119] Portugal, Ribeiro[120]        
Italy, Serra[121]        
France, Pugo-Gunsan[115]        
Croatia, Kresic[122]        
Serbia, Arsic[123]        Hungary, Decsi[124]         
The following paragraphs presents a summary of previous studies that include 
data from 29 different countries also compares populations in various geographic regions.  
The stage of lactation for the sample collection in these studies varies from day 14 up to 
12 months post-partum.  We have chosen to collect and compare information from 
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studies with mature milk and those from a full-term pregnancy.  The size of the sample 
populations in each study ranged from 13 subjects to a maximum of 83 subjects, with an 
average of 39 subjects per study.  The preferred method for analyzing the fatty acids was 
as methyl esters by gas chromatography, although one study using derivatization by 2-
nitrophenylhydrazide and analysis by HPLC is also included.  Table 17 shows the 
distribution of the countries by region. The countries studied are ordered into eight 
regions based on their geographic locations.  Refer to Appendices 1 to 5 for a summary 
of the contents of the most abundant FAs in maternal milk in these 29 countries. 
Palmitic acid is the major saturated fatty acid in human milk.  Italy, Sweden, 
France, and Nigeria have the highest levels (25.00 – 29.26%) of this saturated fatty acid, 
while Chile, Mauritius, China and Canada (18.50 – 18.80%) have the lowest.  Lauric acid 
(C12:0), myristic acid (C14:0), and stearic acid (C18:0) are the next most abundant SFA 
present in human milk. The mean amounts found for each of them are 6.87%, 8.28%, and 
5.95%, respectively.  Nigeria, Phillipines and Iraq show higher amounts of lauric and 
myristic acids in milk, which range up to 23 weight % a value almost double the median 
for the rest of the countries’ data collected in this review.  This tendency (toward high 
levels of medium length FA) has been shown to be common in countries with a high-
carbohydrate and low fat intake diet, which leads to a high percentage of de novo 
synthesis from glucose in the mammary gland [125].   
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Figure 30. Fatty acids concentrations in human milk summarized by geographic regions of the world a) SFA: palmitic acid, mean=21.5% w/w; b) MUFA: oleic acid, mean=29.8%. w/w.  (       ) represents the mean amount.  
MUFAs are higher in the European, North Asian, and North American regions.  
Oleic acid is the major MUFA in human milk and it is also the most abundant of all the 
fatty acids present.  The average amount of oleic acid across all countries was 29.8 
weight % (see Figure 29).  The Oleic acid content in milk is higher than average in most 
of the highly-developed countries including Canada, US, Australia, and among many 
countries in Europe.  Oleic acid levels in human milk are produced by de novo synthesis 
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as well as from dietary intake.  Consumption of animal fat and vegetable oils like olive 
and canola oil increases the concentrations of oleic acid in human milk. 
 
 
 
Figure 31. Essential PUFAs summarized by geographic regions over the world A) Linoleic acid, mean=13.5% w/w. B) α-linoleic acid, mean=1.2% w/w. (       ) represents the mean amount.  
Human milk provides the essential PUFAs (LA, ALA, DHA, AA, and other long 
chain PUFAs) to breastfed infants.  These FA in human milk are important for the new 
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born for different reasons: 1) they are a major energy source, 2) they are necessary to 
support appropriate cell growth, and 3) they are required for normal growth and 
maturation of critical organ systems, particularly the brain and the eyes.   
The amounts of essential fatty acids, LA (C18:2n-6) and ALA (C18:3n-3), in 
human milk are determined by the maternal diet.  Mauritius has the highest amount of LA 
among all the countries (26.85% w/w).  South American countries have elevated levels of 
LA. This is understandable in countries such Brazil and Argentina, where consumption of 
red meat is traditionally higher than for other populations.  Another contribution to the 
high levels of LA in countries such as Chile and Mexico is the frequent intake of corn.  
Some countries in the Middle East such as Israel also showed a high amount of LA 
(20.00%).  On the other hand, Nepal, Western India, and Nigeria have the lowest 
amounts of LA (~ 7-7.91% w/w).   
 ALA (n-3) can be obtained in the diet through intake of vegetable oils and nuts 
(for example flax seed oil, soy bean oil, and walnuts).  The amounts of ALA present in 
human milk are on average approximately ten times lower than those of LA according to 
our review of the literature (see Figure 30).  
AA, EPA and DHA found in human milk may originate from the maternal diet or 
from synthesis from LA and ALA in the maternal tissues [96].  The amounts of AA in 
human milk found in our review range between 0.16–1.4 %w/w of total fatty acids, and 
the amount of DHA range from 0.12–0.99 % w/w of total fatty acids.  In the publication 
by Brenna et al. in 2007 [126],  it was stated that the variation of the levels of AA are 
lower than those of DHA in mature milk. Reviewing data collected from most recent and 
geographically diverse populations leads us to disagree with the conclusion. 
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Figure 32. Long Chain-PUFAs by country. A) AA, mean=0.51% w/w and median=0.46% w/w. B) DHA, mean=0.32% w/w and median=0.23% w/w. 
* no data reported. (       ) represents the mean amount and (       ) represents the median.  
We determined the mean calculated amount of AA found in milk to be 0.51 
weight % (compared with 0.47% reported by Brenna et al.[126]), and the median was 
0.46 weight %.  The mean value calculated for DHA content in human milk was 0.32 
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weight %. This was consistent with the report mentioned above, and the median was 0.23 
weight % [126].  Studies agreed that the differences of the levels in DHA in human milk 
from women living in different regions depend on maternal diet [97, 104].   
Since all the data reported here were not normalized in any statistical manner for 
this review, we have presented the unweighted median and the means of the values.  
Although we have included many countries, not all regions of each country can be 
sampled because of the nature of each study.  There have been more studies conducted in 
the developed countries, for example those in Europe, than in the less developed 
countries.  By contrast, in Africa data were available for only two countries.  In assessing 
the levels of DHA, we have relied on the review by Brenna et al. that includes 84 
publications on DHA to augment data we have been able to independently collect and 
review. 
It has been observed that most of the AA in human milk does not arise from 
dietary LA conversion but instead can be traced to maternal stores [127].  The 
biosynthesis of DHA and AA is slow; consequently, higher amounts of DHA in serum 
during gestation and lactation can be best achieved by consumption of food rich in this 
PUFA or by supplementation, as has been suggested by different studies [128, 129].  
 The highest amounts of DHA were found in the maternal milk of Japanese, 
Philippine, Bolivian, and West Bengalese (in India) women with amounts ≥0.69 weight 
%.  All of these populations have a high intake of fish.  Japan and Philippines are island 
countries, while West Bengal ranks among the top rural areas in India for fish 
consumption.  The Bolivian population studied was located in the region of the Amazoni 
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where consumption of river fish is high.  By comparison, the US and Canada have a low 
average for DHA in maternal milk.  
 From this brief review we can conclude that the FA composition of human milk is 
positively affected by the mother’s diet and varies with geographic location.  Certainly all 
of the FAs are influenced by the dietary intake, but it evident that the most variable FA 
among these populations are the medium-chain SFA and DHA.  
 In the following section, we describe our own results for the analysis of the fatty 
acid composition of human milk in a Peruvian population.  We have compared the FAs’ 
longitudinal variation during a three week period for the first month post-partum.  The 
amounts of 29 FAs are reported.  Discussion focuses on the levels of LA, ALA, and DHA 
since they have such an important role for the healthy development of new born infants.  
The profiles found in our data are compared with those from other studies that were the 
topic of the preceding review. We have included a brief qualitative description comparing 
the principal FA with results from a food questionnaire.   
 
3.3. Research Methods: 
3.3.1. Study population 
The participants in this study were 74 Peruvian mothers having a mean age of 
26.3 years and BMI of 28.8 ± 4 (information available for 69 participants).  All 
participants were in their first pregnancy and had no chronic health concerns.  All of the 
deliveries occurred after the full 37 weeks of gestation.  All volunteers were informed 
about the study and signed an IRB consent document.  
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3.3.2. Sample collection  
Milk samples from 25 volunteers were collected at three time periods during 
lactation: the second, third, and fourth weeks after birth. Milk samples from 50 volunteers 
were collected only during the fourth week after birth.  All samples were collected using 
electric Medela Lactina Select breast pumps, between 9 am and 12 pm. All the 
collections were done at the volunteers’ home by appointment.  Mothers expressed milk 
for 10 minutes from a breast that had not been suckled for two hours.  After gentle 
mixing, 20 ml of milk were placed in polypropylene vials.  The samples were stored at    
-20°C for approximately one week at the study site.  Samples were transferred weekly to 
storage at -80°C until they were shipped overnight to our laboratory at Florida 
International University.  Samples were shipped frozen in dried ice. 
3.2.3. Food frequency questionnaire 
All participants were asked about their food consumption practices using a short 
questionnaire prepared by our nutritionist colleague in the field and based on the usual 
food intake habits in the area.  Diet records were collected during the appointment while 
milk was being expressed.  The data about the mothers’ dietary intake were collected 
based on food frequency intake during a month.  Portion size was not assessed. 
3.3.4. Chemicals and instruments 
Methanol (anhydrous purity ≥99.8%), toluene (HPLC purity ≥99.9%),  acetyl 
chloride (purity ≥99.0%), and anhydrous potassium carbonate (K2CO3) were used as 
solvents and reagents. GC standards include: methyl tridecanoate (C13),  Supelco 37 
Component fatty acid methyl ester (FAME) mix, methyl laurate (C12), methyl palmitate 
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(C16), methyl oleate (C18), and methyl arachidonate (C20). All solvents, reagents and 
standards were purchased from Sigma-Aldrich. 
The standard solution mix, Supelco, contained the following FAMEs components: 
cis-13,16-Docosadienoic acid methyl ester 2 wt. %, cis-4,7,10,13,16,19-Docosahexaenoic 
acid methyl ester 2 wt. %, cis-11,14-Eicosadienoic acid methyl ester 2 wt. %, cis-
5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. %, cis-8,11,14-Eicosatrienoic acid 
methyl ester 2 wt. %, cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. %, cis-11-
Eicosenoic acid methyl ester 2 wt. %, Methyl cis-10-heptadecenoate 2 wt. %, Methyl 
hexanoate 4 wt. %, Methyl γ-linolenate 2 wt. %, Methyl arachidate 4 wt. %, Methyl 
arachidonate 2 wt. %, Methyl behenate 4 wt. %, Methyl butyrate 4 wt. %, Methyl 
decanoate 4 wt. %, Methyl dodecanoate 4 wt. %, Methyl elaidate 2 wt. %, Methyl erucate 
2 wt. %, Methyl heneicosanoate 2 wt. %,Methyl heptadecanoate 2 wt. %, Methyl 
linoleate 2 wt. %, Methyl linolelaidate 2 wt. %,Methyl linolenate 2 wt. %, Methyl 
myristate 4 wt. %, Methyl myristoleate 2 wt. %Methyl oleate 4 wt. %, Methyl octanoate 
4 wt. %, Methyl palmitate 6 wt. %, Methyl palmitoleate 2 wt. %, Methyl pentadecanoate 
2 wt. %, Methyl cis-10-pentadecenoate 2 wt. %, Methyl stearate 4 wt. %, Methyl 
tricosanoate 2 wt. %, Methyl tetracosanoate 4 wt. %, Methyl tridecanoate 2 wt. %, 
Methyl undecanoate 2 wt. %, and Methyl cis-15-tetracosenoate 2 wt. %. 
The analyses were carried-outusing a Hewlett Packard 6890 gas chromatograph 
equipped with a flame ionization detector (FID).  FAME was separated on a silica 
column (30 m x 0.20 mm ID) coated with SP-2330 stationary phase poly(80% 
biscianopropyl-20% cyanopropylphenylsiloxane), having a 0.20 µm film thickness. 
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3.3.5. Determination of FAME in human milk  
Fatty acids were converted to methyl esters following the method used by Lopez-
Lopez and co-workers [130]. 100 µL of human milk sample was placed in a 16 x 125 mm 
screw Teflon cap Pyrex tube with a magnetic stirring bar, together with 40 µL of a 
toluene solution containing 3 µg/ µL tridecanoic acid methyl ester, and 2 mL of a 4:1(v/v) 
solvent mixture of methanol/toluene.  While stirring, 200 µL of acetyl chloride was 
slowly added and then the tube was sealed. The tube was transferred to a 100°C water 
bath and allowed to react for 1 hour.  After reaction, the tube was transferred to an ice 
bath to stop the reaction and 5 mL of 6% K2CO3 solution was added to neutralize the 
solution.  The tube was then vortexed followed by centrifugation (3000 g) for 10 minutes. 
The toluene top layer was transferred to a 2 mL glass vial, closed with a screw cap and 
stored at -20°C prior to analysis by GC.  
3.3.6. Gas Chromatography conditions 
The sample, 1µL, was manually injected using a syringe in a splitless injector 
mode. The injector and detector temperatures were 250°C and 270°C, respectively. The 
oven temperature was programmed as follows: initial temperature 130°C for 3 minutes, 
increasing by 7°C/ min to 180°C, then increasing by 6°C/ min to a final temperature of 
240°C for 5 minutes.  Helium was used as the carrier gas, with a linear velocity of 22.5 
cm/s, and nitrogen was the make-up gas. 
3.3.7. Identification and quantification of fatty acids 
The standard Supelco FAME mix solution was used to identify the fatty acids. 
Confirmation of the peaks was accomplished by gas chromatography/mass spectrometry. 
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Eq. 1 
Retention times were determined using the Standard FAME mix solution and C13 was 
used as an internal standard. Calculation of the amounts of fatty acids was based on peak 
areas relative to the internal standard. 
3.3.8. Calculations 
The response factor (Ri) was determined [131] for each fatty acid in the standard 
mix solution by using the peak areas and the amounts of FAME in the mixture, using the 
following formula: 
ܴ݅ = (஺௜)(ௐ஼ଵଷ)(஺஼ଵଷ)(ௐ௜) 
where Ri is the response factor for the FAME i, Ai is the peak area of the individual 
FAME in the standard mix solution, WC13 is the amount of C13 in the mix solution, and 
Wi is the amount of the ith FAME in the standard mix solution. The amount of each fatty 
acid was calculated using the following equation: 
ܳ݅ = (஺௣௜)(ଵଶ଴)(஺௣஼ଵଷ)(ோ௜)  μ݃ 
 
where Qi is the amount of individual FAME component i in the sample, Api is the peak 
area of this individual fatty acid in the sample, ApC13 is the area peak of the internal 
standard, C13, added to the sample, and Ri is the response factor for the individual 
FAME from equation 1.  All the results obtained from the samples were converted to 
percentage and expressed as % of total fatty acids. 
Eq. 2 
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3.3.9 Partial validation protocol 
For method validation the linearity, limit of detection (LOD), limit of 
quantification (LOQ), and precision (repeatability) were calculated following the 
methodology for parameter and test validation using “Validation of analytical methods” 
by Ludwig Huber [132].  
 
Table 17. Amounts of fatty acid methyl esters (µg) used to prepare calibration curves relative to the internal standard. 
 Standard 
Solution 1 
Standard 
Solution 2 
Standard 
Solution 3 
Standard 
Solution 4 
Standard 
Solution 5 
C12 43.50 266.75 666.25 1132.50 1998.75 
C16 60.00 630.00 1759.75 2495.00 3939.50 
C18 131.00 971.00 2913.00 4855.00 7282.50 
C20 3.75 10.00 62.50 132.50 250.00 
 
To check for linearity, calibration curves for the FAMEs C12, C16, C18, and C20 relative 
to the internal standard (C13) were plotted using five different, increasing concentrations 
prepared in triplicate for each standard.  The amount of C13 was kept constant for all the 
solutions at 120µg. The increasing amounts for each standard are shown in Table 18.  A 
calibration curve for the internal standard C13 was plotted, using six different 
concentrations (0.02, 0.1, 0.25, 0.75, 1.5, and 3 µg/µL) run in triplicate, versus their peak 
area count.  LOD was calculated using the standard error (STEYX) of the predicted y-
value for each x-value in the regression line, the slope of the regression line, and using 
Equation 3 [133]:  
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Eq. 3 ܮܱܦ = ௌ்ா௒௑ௌ௟௢௣௘ ∗ 3 
The LOQ was determined as the lowest concentration that we validated in terms of 
precision and was calculated as ten times the LOD.   
In order to check for recovery in the matrix, aliquots of four solutions containing 
increasing amounts (see standard solutions 2 to 5 shown in Table 18) of C12, C16, C18, 
and C20 were added to a same milk sample that was randomly selected from the group of 
collected samples.  Each sample was analyzed in 4 replicates.  The internal standard was 
added to each solution and kept at a constant amount of 120 µg in all four solutions.  The 
precision was determined by calculating the repeatability of the method.  The same 
sample was analyzed six times during the same day.  For reproducibility of the method, 
the same sample was analyzed on four different days and six different times during each 
day. 
3.3.10. Statistical Analysis 
Data were analyzed using Statistical Packages for Social Sciences version 21.0 
(SPSS Inc. Chicago, IL, USA).  For comparison a two-way ANOVA test was 
conducted for a group of 26 subjects who donated milk samples during the three 
consecutive weeks of the study. 
 
3.4. Results 
The method of Lopez-Lopez [130] was used here to measure FAs.  The method’s 
experimental conditions were adapted to our instrument and tested for partial validation.
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Figure 33. GC-MS of FAME standards. 
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Figure 34. Example of a GC-MS chromatogram of a maternal milk sample. 
  
76  
Table 18. Retention times and response factors for FAMES calculated from the standard mixture run by GC-FID. 
 Fatty acids Retention time (minutes) Weight (%w/w) Ri 
1 C10:0 5.08 4 0.82 
2 C12:0 6.97 4 0.94 
3 C13:0 internal standard 8.08 2 1.00 
4 C14:0 9.26 4 1.11 
5 C14:1n-5 10.11 2 1.10 
6 C15:0 10.43 2 1.19 
7 C15:1n-5 11.28 2 1.14 
8 C16:0 11.63 6 1.20 
9 C16:1n-7 12.30 2 1.18 
10 C17:0 12.75 2 0.99 
11 C17:1n-7 13.45 2 1.17 
12 C18:0 13.88 4 1.04 
13 C18:1t9 14.30 2 1.07 
14 C18:1n-9 14.47 4 1.10 
15 C18:2n-6 15.41 2 1.08 
16 C20:0  16.02 4 0.93 
17 C18:3n-3 16.43 2 1.07 
18 C20:1n-9 16.59 2 0.88 
19 C21:0 17.14 2 0.76 
20 C20:2n-6 17.47 2 0.87 
21 C22:0 17.98 4 0.64 
22 C20:3n-3 18.06 2 0.83 
23 C20:3n-6 18.47 2 0.73 
24 C20:4n-6  18.59 2 0.81 
25 C23:0 19.09 2 0.59 
26 C22:2n-6 19.45 2 0.67 
27 C20:5n-3 19.61 2 0.83 
28 C24:0 19.97 4 0.54 
29 C24:1n-9 20.52 2 0.56 
30 C22:6n-3 22.21 2 0.67 
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Identification and quantification of FAMEs was carried using a commercially 
available standard mixture solution.  We were able to identify 32 fatty acid methyl esters 
from the standard mixture (Figure 34) using the relative retention times.  All the FAs 
shown in Table 18 were identified in human milk, in Figure 15 FAs: 13,19,22,23, and 27 
are in low amounts (they could not be label in the figure).   
Figure 35. Calibration curves for FAMEs relative to the internal standard with different chain lengths (a) C12, (b) C16, (c) C18, and (d) C20.  Amounts used are shown in Table 7. 
The response factors for all of the fatty acids identified were calculated using the 
peak areas and the amounts in the standard mixture using Eq. 1.  The factor response for 
peak 31 (C11:0, undecanoic methyl ester) was not calculated because it is not identified 
in human milk.  Factor response for peak 32 (C18:2n-6t, linoleladic methyl ester) was not 
calculated because it was noticed that it could co-elute with nonadecanoic methyl ester, 
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as C18:2n-6t is present in very low concentrations in human milk.  Linear regression fits 
for four different standard FAMEs relative to the internal standard showed a good 
linearity response as shown in Figure 35. 
The concentration ranges for the four standards tested were different.  They were 
chosen to fall within the ranges reported to be found in mature milk [104].  The 
regression lines show a strong correlation in all cases and we can confirm the linearity of 
the FAMES relative to the internal standard in the ranges chosen for each standard 
FAME. 
 
Table 19. Repeatability measurements from five replicates (mean ± %RSD). 
 Mean (µg/100µL) % RSD  Mean (µg/100µL) % RSD 
C10:0 66.00 5.78 C18:3n-3 49.17 2.77 
C12:0 405.51 3.37 C20:1n-9 7.65 7.98 
C14:0 466.49 1.62 C21:0 2.48 8.97 
C14:1n-5 4.47 6.44 C20:2n-6 15.84 8.49 
C15:0 6.76 9.06 C22:0 1.59 6.01 
C15:1n-5 2.66 9.56 C20:3n-3 11.21 6.55 
C16:0 753.79 1.62 C20:3n-6 1.83 5.42 
C16:1n-7 69.60 1.16 C20:4n-6 18.14 8.27 
C17:0 7.66 2.48 C23:0 2.28 6.63 
C17:1n-7 5.64 6.24 C22:2n-6 2.61 8.47 
C18:0 148.59 4.25 C20:5n-3 3.15 9.95 
C18:1t9 8.73 5.34 C24:0 2.57 6.80 
C18:1n9 704.17 3.31 C24:1n-9 1.80 3.71 
C18:2n6 591.46 3.59 C22:6n-3 13.00 9.27 
C20:0  6.00 4.31    
 
The precision of our method was calculated for repeatability using one milk 
sample, as the matrix and the extraction was made in five replicates during the same day. 
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The results are shown in Table 20.  The precision was acceptable for all major fatty acids.  
Fatty acids that are present in the matrix sample with a concentration higher than 10% 
showed a low RSD between 1.6 – 3.6%.  On the other hand, the RDS was higher for 
those with lower concentrations (< 20 µg/100µL). The RSD was found to be 4.3 – 9.3% 
for those fatty acids present in less than 0.4% concentration.   
A calibration curve for the internal standard was plotted (Figure 36).  STEYX was 
calculated to be 27.54 and using the slope, LOD and LOQ were calculated to be 0.27 
µg/µL and 2.73 µg/µL respectively. 
 
 
Figure 36. Calibration curve for to the internal standard C13. 
 
Table 20. Total % of fat in all milk samples during 2nd, 3rd and 4th week after delivery. 
 N Range Mean (%) SEM 
W2 30 1.25-5.58 3.45 0.18 
W3 28 0.79-5.28 3.33 0.21 
W4 74 1.20-8.22 3.77 0.16 
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Table 21. Fatty acid composition of transitional and mature milk (%w/w) in all subjects. 
 Transitional milk 2
nd   Week N=30 Mature milk 3
rd Week N=28 Mature milk 4
th Week N=74 
 Min Max Mean SEM Min Max Mean SEM Min Max Mean SEM 
C10:0 1.05 6.07 2.11 0.18 0.94 3.65 1.97 0.11 0.87 4.56 2.05 0.08 
C12:0 2.85 18.85 7.59 0.65 2.74 12.38 6.79 0.41 2.97 15.39 7.42 0.28 
C14:0 2.09 14.83 6.31 0.55 2.31 12.80 5.71 0.41 2.24 11.75 5.97 0.23 
C15:0 0.11 0.46 0.23 0.02 0.08 0.35 0.21 0.01 0.10 0.48 0.20 0.01 
C16:0 17.04 24.51 20.13 0.42 13.44 28.34 20.27 0.66 14.91 27.52 19.44 0.27 
C17:0 0.17 0.48 0.30 0.01 0.19 0.55 0.30 0.02 0.20 0.57 0.30 0.01 
C18:0 3.59 6.61 5.30 0.11 4.00 6.78 5.40 0.13 3.71 14.52 5.54 0.16 
C20:0 0.24 0.50 0.36 0.01 0.11 0.58 0.39 0.02 0.16 0.63 0.38 0.01 
C21:0 0.12 0.68 0.26 0.02 0.08 0.72 0.25 0.02 0.11 0.44 0.21 0.01 
C22:0 0.10 1.06 0.20 0.03 0.11 0.49 0.20 0.01 0.09 0.80 0.19 0.01 
C23:0 0.13 0.50 0.26 0.01 0.14 0.46 0.29 0.01 0.12 0.52 0.26 0.01 
C24:0 0.29 0.74 0.48 0.02 0.32 0.86 0.53 0.02 0.20 0.94 0.41 0.01 
total SFA   43.52    42.31    42.37  C14:1n-5 0.08 0.37 0.17 0.01 0.06 0.33 0.17 0.01 0.06 0.62 0.18 0.01 
C15:1n-5 0.08 0.62 0.21 0.02 0.12 0.60 0.29 0.03 0.05 0.64 0.25 0.01 
C16:1n-7 1.05 4.95 2.66 0.16 1.56 4.57 2.83 0.17 1.11 4.75 2.71 0.09 
C17:1n-7 0.10 0.27 0.17 0.01 0.11 0.32 0.19 0.01 0.09 0.33 0.18 0.01 
C18:1t9 0.16 2.08 0.53 0.07 0.19 1.64 0.52 0.06 0.18 1.39 0.50 0.03 
C18:1n-9 17.90 29.87 25.97 0.61 20.05 31.33 26.45 0.57 19.43 33.01 25.85 0.32 
C20:1n-9 0.29 0.70 0.41 0.02 0.31 0.68 0.46 0.02 0.08 0.57 0.42 0.01 
C24:1n-9 0.13 0.47 0.26 0.02 0.16 0.54 0.27 0.02 0.10 0.64 0.20 0.01 
total MUFA   30.38    31.19    30.29  
C18:2n-6 11.48 29.92 20.46 0.76 12.80 32.79 20.95 0.90 2.91 28.59 21.87 0.51 
C20:2n-6 0.59 1.22 0.82 0.03 0.59 1.25 0.85 0.03 0.52 1.14 0.81 0.01 
C20:3n-6 0.05 0.98 0.14 0.03 0.07 0.96 0.16 0.03 0.06 0.90 0.13 0.01 
C20:4n-6 0.11 1.49 0.98 0.05 0.73 1.98 1.03 0.05 0.58 1.57 0.85 0.02 
C22:2n-6 0.10 1.36 0.28 0.04 0.14 0.59 0.24 0.02 0.09 0.40 0.17 0.01 
total PUFA n-6   22.69    23.23    23.83  
C18:3n-3 0.85 2.31 1.59 0.07 0.15 2.78 1.52 0.10 0.66 2.71 1.81 0.05 
C20:3n-3 0.44 1.34 0.84 0.04 0.50 1.51 0.90 0.04 0.09 1.43 0.79 0.02 
C20:5n-3 0.05 0.42 0.15 0.02 0.06 0.26 0.12 0.01 0.04 0.35 0.12 0.01 
C22:6n-3 0.44 3.37 0.84 0.10 0.48 1.51 0.74 0.05 0.38 1.99 0.78 0.04 
total PUFA n-3   3.41    3.28    3.50  
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Table 22. Fatty acid composition of mother’s milk (%w/w) for the same subjects. 
  Transitional milk 2nd  Week N=26 Mature milk 3
rd  Week  N=26 Mature milk 4
th  Week N=26 
  Min Max Mean SEM Min Max Mean SEM Min Max Mean SEM 
C10:0 1.13 6.07 2.18 0.20 0.94 3.65 1.95 0.12 1.35 4.56 2.27 0.16 
C12:0 4.14 18.85 7.85 0.71 2.74 12.38 6.87 0.43 3.22 15.39 7.78 0.58 
C14:0 2.87 14.83 6.45 0.59 2.31 12.80 5.86 0.43 2.24 11.42 6.09 0.47 
C15:0 0.11 0.43 0.22 0.02 0.11 0.35 0.21 0.01 0.12 0.38 0.20 0.01 
C16:0 17.04 24.07 20.02 0.43 16.27 28.34 20.57 0.65 14.97 23.50 19.66 0.46 
C17:0 0.17 0.48 0.29 0.02 0.19 0.55 0.31 0.02 0.20 0.40 0.29 0.01 
C18:0 3.59 5.92 5.21 0.11 4.00 6.78 5.42 0.14 4.20 8.23 5.32 0.18 
C20:0 0.24 0.50 0.36 0.01 0.11 0.58 0.39 0.02 0.27 0.63 0.40 0.02 
C21:0 0.12 0.68 0.26 0.03 0.08 0.72 0.25 0.02 0.12 0.34 0.22 0.01 
C22:0 0.10 1.06 0.20 0.04 0.11 0.49 0.20 0.02 0.09 0.80 0.19 0.03 
C23:0 0.13 0.37 0.25 0.01 0.14 0.46 0.29 0.02 0.14 0.52 0.29 0.02 
C24:0 0.29 0.74 0.46 0.02 0.32 0.86 0.53b 0.02 0.31 0.94 0.44 0.03 
total SFA    43.75     42.86    43.14  C14:1n-5 0.08 0.37 0.17 0.01 0.06 0.33 0.17 0.01 0.09 0.32 0.17 0.01 
C15:1n-5 0.08 0.62 0.21a 0.02 0.12 0.60 0.30 0.03 0.09 0.48 0.24 0.02 
C16:1n-7 1.05 4.95 2.67 0.18 1.56 4.57 2.87 0.18 1.30 4.38 2.59 0.17 
C17:1n-7 0.10 0.27 0.17 0.01 0.13 0.32 0.19 0.01 0.09 0.26 0.17 0.01 
C18:1t9 0.16 2.08 0.53 0.07 0.22 1.64 0.54 0.07 0.18 1.19 0.42 0.05 
C18:1n-9 17.90 29.87 25.93 0.64 20.05 31.33 26.38 0.59 19.43 29.92 25.24 0.55 
C20:1n-9 0.29 0.70 0.41 0.02 0.31 0.68 0.46b 0.02 0.08 0.53 0.40 0.02 
C24:1n-9 0.13 0.47 0.25 0.02 0.16 0.54 0.28 0.02 0.10 0.64 0.22 0.02 
total MUFA    30.34     31.18    29.45  
C18:2n-6 11.48 26.91 20.34 0.78 12.80 27.50 20.41 0.84 14.44 28.59 21.96 0.79 
C20:2n-6 0.59 1.22 0.81 0.03 0.59 1.25 0.83 0.03 0.52 1.12 0.76 0.03 
C20:3n-6 0.05 0.98 0.15 0.03 0.07 0.96 0.16 0.03 0.06 0.20 0.11 0.01 
C20:4n-6 0.11 1.49 0.99 0.05 0.73 1.98 1.04b 0.05 0.62 1.57 0.89 0.04 
C22:2n-6 0.10 1.36 0.28 0.05 0.14 0.59 0.24 0.02 0.10 0.40 0.20 0.01 
total PUFA n-6    22.57     22.69    23.91  
C18:3n-3 0.85 2.31 1.58 0.08 0.15 2.40 1.49b 0.10 0.79 2.65 1.80 0.09 
C20:3n-3 0.44 1.34 0.86  0.05 0.50 1.51 0.91b 0.05 0.09 1.43 0.80 0.05 
C20:5n-3 0.05 0.42 0.14 0.02 0.07 0.26 0.13 0.01 0.04 0.32 0.13 0.01 
C22:6n-3 0.44 1.56 0.76 0.05 0.48 1.51 0.75 0.05 0.39 1.99 0.75 0.07 
total PUFA n-3     3.34       3.27       3.49   a Significantly different (p < 0.05) between transitional and mature milk from 3rd. week 
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b Significantly different (p < 0.05) between mature milk from 3rd. and 4th.week  
The results of total % fat analyzed in all the 74 subjects are shown in Table 21. 
The average results for the extraction of FAMEs from milk samples from weeks 2, 3 and 
4 after delivery are shown in Table 22.  Data were collected in triplicates for a group of 
26 mothers during three consecutive weeks.  The results for the FAME extractions and 
total % fat of the previously mentioned group are shown in Tables 23 and 24, 
respectively. 
 
Table 23. Total % of fat in milk samples during week 2, 3 and 4th after delivery for the same subjects. 
  N Range Mean (%) SEM 
W2 26 1.25-5.58 3.40 0.20 
W3 26 0.79-5.28 3.26 0.22 
W4 26 1.20-6.43 3.26 0.28 
 
No significant difference was found for the total % of fat among the three weeks 
studied.  Only 5 FAs (C24:0, C20:1n-9, C20:4n-6, C18:3n-3, C20:3n-3) were 
significantly different between week 3 and week 4 of lactation.  ALA (C18:3n-3) is the 
only member of this group that is an essential fatty acid. The rest are long chain fatty 
acids.  In addition, there was one MUFA, C15:1n-5, which showed a significant 
difference between transitional milk (week 2) and mature milk form the 3rd week.  
Average results from the frequency intake of food from animal sources are shown in 
Table 25. 
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Table 24. Food frequency intake. 
Food frequency during one month N = 74 
 Min Max Average (times per month) Std. dev. Chicken, poultry 4 63 29.35 13.20 Red meat 0 63 5.51 8.81 
Chicken's liver 0 60 8.39 10.93 
Cow's liver 0 8 0.72 1.68 
Fish 0 34 5.77 6.68 
Sea food 0 9 0.99 2.02 
Dairy products (milk, cheese, and yogurt) 0 120 39.50 28.53 
Eggs 0 42 15.28 10.19 
 
3.5. Discussion and Conclusions 
 This study evaluated the fatty acid profiles of 74 healthy Peruvian women with an 
omnivorous diet.  Comparable replicated measurements for 26 subjects from the available 
population sample were evaluated longitudinally to compare FA variation over three 
weeks during the first month of lactation.  The results from the latter group are presented 
in Table 23. A two-way ANOVA test was run and the results showed a significant 
difference for six fatty acids (see Table 26). 
Table 25. FAs with a significant difference between weeks 2 and 4 of lactation. 
Fatty acid p value Groups Change 
C24:0 0.016 3rd week & 4th week Decreased 
C15:1n-5 0.034 2nd week & 3rd week Increased 
C20:1n-9 0.027 3rd week & 4th week Decreased 
C20:4n-6 AA 0.011 3rd week & 4th week Decreased 
C18:3n-3 ALA 0.008 3rd week & 4th week Increased 
C20:3n-3 0.019 3rd week & 4th week Decreased   
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Only one MUFA (C15:1n-5) showed a difference between transitional (2nd week) 
and mature milk (3rd week).  The other FA showed significant differences between 
mature milk during the 3rd and 4th weeks.  All of these were long chain fatty acids and 
one of them is the essential fatty acid ALA (C18:3n-3).   
In the literature we find that total lipid levels are usually reported to increase with 
time during lactation [75]. We did not see a consistent significant increase in the total fat 
content in milk during the 3 week period of this study.  Studies [119, 121, 134] have 
shown that the largest variation of FA levels in human milk occurs during the transitional 
period from colostrum to mature milk. Another longitudinal study [135] have reported an 
increase from colostrum to transitional and then a slightly decrease from transitional to 
mature milk, all only within the first month of lactation.  Our results agree and show that 
there is a decrease from transitional milk to mature milk.  Most longitudinal studies have 
not reported the variations during the first month week by week to form a basis for a 
general conclusion.  Our study is unique in that we were able to study the variations week 
by week during the first month.   
Significant variation between transitional (2nd week) and mature milk (4th week or 
later) has been reported for only a few FA and shows an influence from the mothers’ diet.  
In general, results showing significant longitudinal differences in total milk fat and 
individual components are not universally reported.  We suspect that for our study the 
few significant differences are most probably due to the mothers’ diet.  In particular, we 
note that ALA is of dietary origin and its level in milk varies among regional populations 
in a manner that reflects dietary intake from our review above. 
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Table 26. Total amounts (% w/w) variation during the first month by type of FA. 
 Initial week (transitional milk) Last  week (mature milk) % ∆ 
total SFA 43.75 43.14 -1.39 
total MUFA 30.34 29.45 -2.93 
total PUFA n-6 22.57 23.91 5.96 
total PUFA n-3 3.34 3.49 4.59 
 
Figure 37. Total amounts (% w/w) variation during the first month by type of FA. 
 
When comparing the total % levels for each group by fatty acid type (see Figure 
37), we found that there is a variation between the 2nd week (transitional) and 4th week 
(mature milk).  Although the values of SFA and MUFA decreased, it was not by 
significant amounts.  The amounts of n-6 and n-3 PUFAs increased 6.0% and 4.6% 
respectively, see Table 27 above. 
As seen, with the exception of six FA mentioned above, the amounts of the FAs 
evaluated were not observed to be significantly different among the three weeks of 
lactation studied (2nd-4th week)   Recognizing this, we have analyzed results from the 
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fourth week of lactation, see Table 14, which represents a much larger sample population 
(all 74 subjects).  These data enable us to provide a quantitative description of the FA 
profiles in the milk from this Peruvian population. 
 Figure 38. Histogram, all countries including Peru, for A) Palmitic acid, Mean = 21.77%, N = 29. B) Oleic acid, Mean = 30.3%, N=31. Blue dashed line represents the mean of all countries. Red square represents Peru. 
 
SFA constitutes 42.37% of the total fatty acids found in milk of the Peruvian 
mothers in our study, results which are similar to levels found in many countries in 
Europe, mean = 42.15% and South America, mean = 42.18% (see Appendix 1 and 2).  
The most abundant SFA in milk was Palmitic acid with 19.44% and accounts for almost 
half of the total SFAs.  The amount of palmitic acid in milk of Peruvian mother’s is  
lower than the mean of that for all countries compared in our review of the literature (see 
Figure 38) but falls within the range found for all countries in the Americas (South and 
North). The level of palmitic acid although lower, is similar to that found in Chinese and 
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Japanese mothers (see Appendix 4).  In our study the amount of stearic acid, 5.54%, was 
found to be near the average when compared with many countries studied worldwide 
(mean level is 5.95%).  The levels of the fatty acids that are synthesized de novo in the 
mammary ducts (capric = 2.05%, lauric = 7.42%, and myristic acid = 5.97 %) are all 
found within the standard ranges seen in populations from other South American 
countries (Chile and Brazil). They comprise a little more than one third of the total SFA. 
 MUFA account for 30.29% of total fatty acids in milk of Peruvian mothers, which 
is lower than the range for values found in other South American countries (31.20-
34.41%).  The major component is oleic acid (25.85%) and the level was lower than in all 
countries in Europe, North America, Australia, China and Japan, see Figure 38.  The 
content of oleic acid in the milk of Peruvian mothers falls in the lowest quartile of the 
range for all the countries reviewed. The oleic acid content is close to the levels found in 
the milk of Brazilian, Chilean, and Brazilian mothers.  This finding may reflect of a lower 
intake of animal fats and olive oil than in Mediterranean countries such as Italy and 
Spain. The finding is also consistent with a lower intake of soybean oil and other soy 
derived products that are common in diets of mothers in Asian countries.   
Table 27. Elaidic acid in human milk in different countries (% w/w). 
Country Author [reference] 
Italy Haddad [95] 
Germany Precht [101] 
Bolivia Martin [114] 
Turkey Samur [136] 
US Martin [114] 
Neatherlands Mueller [137] 
Brazil Barenhauser [134] 
Peru OUR STUDY 
N 8 40 35 50 35 185 10 74 
lactation stage > 15 day <8 days 3-6 mo. 3-4 mo >6 mo. 1 mo. >16 day 3 week 
C18:1t9 1.21 0.37 0.21 1.96 1.23 0.61 1.67 0.50 
 
The only TFA measured in our study was elaidic acid (C18:1,t9).  There are a 
small number of publications that include elaidic acid in their results.  A comparison of 
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our results with those from other populations is presented in Table 27.  Many of the 
studies have compared the results of TFA in human milk with diet, and have concluded 
that eating habits determine the levels of TFA.  TFAs in different populations are markers 
of the influence of processed, high fat content foods.   Mueller et al.[137] indicated that a 
diet rich in dairy products and/or meat and dairy of organic origin was associated with a 
lower ratio of elaidic acid to C18:1t11 in milk.  It was suggested that this isomer ratio be 
taken into account when studying the health-related impact of TFA levels in foods.  The 
amount of elaidic acid found in the milk of Peruvian mothers was found to be less than 
half the level of US mothers and supports the conclusion that the intake of TFA in the 
diet of the Peruvian donors has a lower intake of TFAs from processed food than in the 
US.  During recent decades, the intake of trans-fat has continuously decreased in Western 
diets.  In the US, between 2003 and 2006, trans fat intake dropped to 1.3 grams per 
person per day from 4.6 grams per person per day due to new regulations restricting use 
of trans-fat by the food industry [138].  Thus, when using TFAs as markers in different 
populations, we could assume that the high level of elaidic acid is caused by the influence 
of processed and high fat content food in the American diet as well as in other countries.  
Although the influence of TFA in the new born development is not well understood, 
recently attention has focused on trying to determine if the conversion of LC-PUFAs 
from the essential FA is reduced by the presence of higher levels of TFA.  If this is found 
to be so, it may compromise the neural development in the new born infants.   
The levels of essential fatty acids in mothers’ milk are of special interest because 
of their importance as components of the membrane lipids critical for retina and brain 
development.  The levels of LA and ALA found in the Peruvian mothers’ milk were 
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21.87% and 1.81%, respectively. Both of these are in the highest quartile of distribution 
among the countries studied (see Figure 39).  In more than 50% of all the populations 
reviewed before, LA fell under 15% w/w, and more than 65% of the population fell under 
1.25% w/w for ALA.  The food questionnaire conducted as part of our study revealed 
that the consumption of poultry by these mothers was almost six times more frequent 
than the comsumption of red meat. This dietary choice is consistent with our observation 
of a higher content of PUFAS in Peruvian mothers’ milk. .  In addition, in Peru, vegetable 
oils were found to be preferable to olive oil in the diet, and corn is also frequently in the 
diet [139].   
 Figure 39. Histogram, all countries reviewed, for A) Linoleic acid, Mean = 14.08%, Median = 13.8%, N = 33. B) α-linoleic acid, Mean = 1.12%, Median = 1.05%, N=33. Blue dashed line represents the mean of all countries. Red square represents Peru. 
 
Figure 40 shows the ratios of LA to ALA for the countries reviewed here.  These 
ratios vary from 4.10 to 57.75. The higher ratios represent larger amounts of LA in milk.  
  
90  
This ratio is important since both LA and ALA compete for the same chain 
elongation/desaturation enzymes and high levels of n-6 LA could significantly diminish 
production of essential n-3 EPA and DHA needed by infants for optimal neural 
development.  Higher ratios are indicative of an imbalanced diet resulting in lower n-3 
PUFA biosynthesis. Some researchers have suggested that acceptable LA : ALA ratios 
fall in the range of 5:1–15:1[104], values that have been adopted in European regulations.  
The LA:ALA ratio found for Peruvian mothers in this study was 12.08 and although at 
the higher end of this range, it lies within these guidelines. 
 
Figure 40. LA:ALA ratios for different countries. Peru is represented in red. Dashed line represents the median of all countries=13.6. 
 
LC-PUFAs in the milk of Peruvian mothers were found at relatively high levels.  
In this study, EPA was found to average 0.12% (range = 0.03-0.39%), DHA was 0.78% 
(range= 0.06-1.40%) and AA was 0.85% (range = 0.16 1.4%). Comparing these values to 
recent literature data (see Table 16 and Brenna et al  2007 [126]), both AA and DHA fall 
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in the highest quartile compared to other populations.  Despite the fact that the ratio of 
LA/ALA was 12:1, the ratio of the essential FAs, AA/DHA, was 1:1.  The conversion of 
LA and ALA to AA and DHA is apparently not high, as evidenced by the ratio of 
AA/DHA.  Instead, the result shows that both LC-PUFAs originate not only from the 
synthesis taking place in the mammarian glands from the uptake of LA and ALA, but 
also from transference from diet intake. 
Table 28. DHA content (% w/w) in human milk of US women in studies conducted from 1992-2012. Taken from Brenna et al.[126] and Martin et al.[114]. 
Year Site DHA % 
1992 Connecticut 0.37 
1998 N.S. 0.20 
2000 N.S. 0.15 
2003 Oregon 0.20 
2005 Texas 0.20 
2005 North Carolina 0.21 
2006 N.S. 0.17 
2012 Cincinnati 0.16 
N.S. = not specified 
  The amount of DHA in the milk of our Peruvian study population (0.78%) 
corresponds to samples taken during 2013-2014 in Peruvian mothers. The level of DHA 
is anticipated to be associated with the average frequency for intake of fish and sea food 
of 6.8 times per month obtained from our food frequency questionnaire (see Table 24).  
We have compared the amount of DHA found in the Peruvian population to other studies 
completed in analyzing different geographical regions in the US between 1992 and 2012, 
see Table 28. The median amount of DHA in the US is 0.20% w/w.  The % DHA in the 
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Peruvian population is almost 4 times greater than that found most of the studies for U.S. 
women.  One exception is a study in Connecticut women.  According to the Peruvian 
National Institute of Statistics and Informatics, the average fish and sea food intake per 
capita was 10.2-11.1 kg/year in 2009 in the costal urban area of Peru.  In comparison 
according to the National Oceanic and Atmospheric Organization of the U.S., the average 
American consumed 7.2 kg of fish and shellfish in same year.  For reference we note that 
the annual Japanese consumption in 2013 was 27.3 kg/year.  These data lead us to 
assume that in the Peruvian coastal region intake of sea food is about 30% greater than 
the average intake in the U.S.  The high level of DHA found in milk of Peruvian women 
is most probably caused by the relatively high consumption of fish and sea food in their 
diet.   
 
Table 29. FA concentrations (mg/L) from Peruvian mothers in mature milk (4th week of lactation). N=74. 
 Min. Max. Mean SEM Median LA 1085.5 19203.5 8392.8 463.1 7786.5 
ALA 163.7 1808.8 691.1 38.6 627.7 
AA 134.6 641.1 314.6 13.2 294.2 
EPA 14.3 126.7 42.5 2.2 38.6 
DHA 89.4 903.8 291.1 18.3 259.4 
total n-6 1353.7 20801.7 9122.2   total n-3 299.4 3560.1 1319.1    
The levels of n-6 and n-3 fatty acids are vital for the optimal development of 
healthy infants.  The total amounts of n-6 and n-3 fatty acids in the Peruvian population 
studied were 23.83% and 3.50%.  Although it is not yet clear what the ideal intake of 
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essential fatty acids from mothers’ milk needed for an optimal development is, the Food 
and Nutrition Board of the U.S. Institute of Medicine[140] has established that the 
adequate daily intake (ADI) of n-6 and n-3 fatty acids for infants between 0-6 months 
should be 4.4g/day and 0.5g/day, respectively.  For infants 7-12 months the ADI has been 
set at 4.6g/day and 0.5g/day.  The European Union regulations[141] for infant formula 
establishes intakes of LA at 500-1200 mg/100kcal and for ALA as 50-100mg/100kcal, 
(using 670 kcal/L as a conversion factor); this requirements can be expressed as 3350-
8040mg/L for LA and 335-667 mg/L for ALA.  In addition, other organizations around 
the world [142] also specify adequate intake levels for DHA of 20mg/kg/day for infants 
0-5 months and up to 100mg/day for infants 7- 24 months of DHA. 
Table 30. Human milk FA concentrations (mg/L). Taken from Yuhas et al.[104] 
 
 Table 29 presents the concentrations in mg/L of FA in 74 Peruvian women in 
mature milk. The mean levels reported here for the essential FA and LC-PUFAs meet all 
the international guidelines for adequate intakes of n-6 and n-3 PUFAS recommended for 
infants during the first months.  Moreover, when comparing quantities from Table 29 
with the quantities presented in Table 30 for n-6 and n-3 PUFAs from different countries, 
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we can conclude that dietary supply of essential FA is sufficient in the Peruvian 
population studied during the first month of lactation.   
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CHAPTER IV: Carotenoids in human milk  
Human milk is the sole source of nourishment for most infants during the first 
months of life. Essential fat soluble nutrients including carotenoids that cannot synthesize 
by humans are transported in the emulsified fat globules present in the mother’s milk.  
Both pro-vitamin A and non pro-vitamin A carotenoids act as antioxidants and provide 
protection against chronic diseases [76, 143].  The fatty acid composition of triglycerides 
and in milk changes during lactation.  Colostrum, the secretion produced by the mother’s 
mammary glands during the first days after giving birth [144] is rich in essential nutrients 
and antibodies and the yellow coloration has been suggested to be due to the high 
concentration of carotenoids derived from the mother’s stores  [145].   
As described in the previous chapters, it has been suggested that lutein and 
zeaxanthin as well as the essential polyunsaturated fatty acids (PUFAS) such as linoleic 
acid and α-linolec acid are important in early vision and neural development.  Long chain 
n-3 and n-6 PUFAS, such as docosahexanoic acid (DHA) and arachidonic acid (AA) are 
known to be important in visual function and neural development [39, 99].  All of these 
lipophilic nutrients are acquired by the new born through lactation, and the carotenoids 
are solubilized in the fat globules present in human milk.  The mechanism of transport of 
carotenoids from the mother’s blood stream into milk remains incompletely understood.  
It has been hypothesized that a selective mechanism may be responsible for the transport 
of carotenoids into human milk.  Specifically, because carotenoids are lipophilic in nature 
and co-transported with lipids, it may be that their transport is in association with specific 
fatty acids.  Little information is available about carotenoid transport and so we have 
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analyzed carotenoid levels in human milk during the first month of lactation in an effort 
to improve our understanding [135, 146, 147].  Most of the previously published studies 
reporting measurement of carotenoid levels in human milk [148-150] have focused on 
mature milk obtained from the later stages in lactation.  Our goal here was to increase the 
data base on carotenoid levels in human milk during the first month with the goal of 
improving our understanding of the uptake and transport of carotenoids.  In Chapter 3, 
the amounts of fatty acids measured in the lipid fraction of breast milk samples from 74 
Peruvian new mothers were reported and discussed.  In this Chapter, our measurements 
of the carotenoids found in the milk of these women are presented and correlated with the 
results of our analysis of the individual fatty acids in human milk during the first month 
of lactation.  
 
4.1. Research Methods 
4.1.1 Study population 
The participants in this study were 74 Peruvian mothers having a mean age of 
26.2 years and an average BMI of 27.97 ± 3.98 (BMI was available for 70 participants).  
This was the first pregnancy for all participants and none reported chronic health 
concerns.  All of the deliveries occurred after the full 37 weeks of gestation.  All 
volunteers were informed about the study and signed an IRB consent document.  
4.1.2. Chemicals 
Ethyl alcohol USP grade, potassium hydroxide, butylated hydroxytoluene, USP 
grade (BHT) were all purchased from Sigma-Aldrich or Fisher Scientific. HPLC grade 
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hexane, dichloromethane, methanol, and acetonitrile were purchased from Sigma-
Aldrich. Lutein and zeaxanthin standards were a gift from Industrial Organica S.A.  β-
carotene standard was purchased from Sigma-Aldrich. Methyl pentyl lutein (MPL) and β-
cryptoxanthin standards were prepared and characterized by methods described in 
Chapter 1.  
4.1.3. Instruments 
A Varian ProStar HPLC system coupled to a ProStar 335 photodiode array UV-
visible detection system was used for carotenoid analysis.  A Phenomenex 250 x 4.60mm 
ODS ultracarb 3 µm column (20) of was used for all primary carotenoid separations, with 
a mobile phase consisting of acetonitrile: methanol: triethylamine (85%: 15%: 0.1% v/v) 
and a flow rate of 1 mL/min with a detection at 450nm. Chromatographic data were 
analyzed using the Varian software package. 
4.1.4. Carotenoid analysis in milk samples 
The extraction of the carotenoids from milk samples was carried out following the 
procedure used by Jackson et al. [151].  Milk samples were thawed at room temperature 
and shaken gently to homogenize the sample prior to pipetting an aliquot for analysis. 2 
mL of milk and 200 µg of MPL standard were placed in a Teflon screw cap Pyrex tube 
(15x125 mm).  Saponification of samples was carried out by adding 1.5 mL of 50% (w/v) 
potassium hydroxide and 2.5 mL absolute ethanol to the tube.  After vortexing the tube, 
the contents was placed in a water bath at 37-38°C for 2 hours and the tubes were 
occasionally stirred. Carotenoids were extracted three times from the mixture using 3 mL 
aliquots of hexane containing 0.025% (w/v) BHT. The extracts were combined and 
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evaporated under nitrogen.  The resulting residue was re-dissolved into 80 µL of ethanol 
prior to HPLC analysis. 
4.1.5. Chromatographic separation analysis 
Carotenoid levels in all samples were analyzed by reversed phase HPLC, using a 
Phenomenex 250 x 4.60mm ODS ultracarb 3 µm column (20).  The mobile phase used 
for the separation was a mixture of acetonitrile/methanol/TEA (85%: 15%:0.1% v/v). The 
flow rate was 1 mL/minute and the sample was run at 25°C for 90 minutes. Quantitation 
of the individual components was carried out by comparing the peak areas in 
chromatograms to that of the added internal standard.   
4.1.6. Statistical Analysis 
Data were analyzed using Statistical Packages for Social Sciences version 21.0 
(SPSS In c. Chicago, IL, USA).  For comparison a two-way ANOVA test was 
conducted for a group of 26 subjects that donated milk samples during the three 
consecutive weeks of the study. 
4.2. Results 
We have analyzed the carotenoid content in a total of 133 human milk samples.  
A typical chromatogram obtained for a milk sample is shown in Figure 41.  Analytical 
results of the carotenoid concentrations in maternal milk have been collected and are 
found in Tables 31- 33.  The results for samples obtained during each week post-partum 
are displayed separately:  Week 2 (W2), Week 3 (W3), and Week 4 (W4).   
 
Table 31. Carotenoid concentrations in human milk during the 2nd week of lactation (transitional milk, W2). 
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*** Not detected 
Table 32. Carotenoid concentrations in human milk during the 3rd week of lactation (mature milk, W3). 
Mature milk (week 3 post-partum) (µmol/L) 
Subject Lutein  Zea βcry βcar  Subject Lutein  Zea βcry βcar  
2701 0.06 0.04 0.02 0.02 4702 0.04 0.01 0.01 0.05 
2702 0.04 0.02 *** *** 4703 0.03 0.01 0.01 0.03 
2703 0.08 0.02 *** *** 4705 0.03 0.02 0.03 0.03 
2704 0.04 0.02 *** *** 4706 0.01 0.01 0.02 *** 
2705 0.07 0.03 0.02 *** 4708 0.04 0.02 0.02 *** 
2706 0.05 0.02 0.04 0.04 4709 0.03 0.01 0.03 0.03 
2707 0.05 0.02 0.11 0.03 4710 0.02 0.01 0.02 0.03 
2708 0.04 0.01 0.02 *** 4712 0.13 0.04 0.14 0.09 
2709 0.01 0.01 0.06 *** 4713 0.06 0.03 0.21 0.05 
2710 0.04 0.01 *** *** 4714 0.09 0.05 0.06 0.05 
2711 0.04 0.02 0.03 *** 4715 0.03 0.02 0.04 0.03 
2713 0.08 0.03 0.13 0.10 4716 0.03 0.02 0.14 0.02 
2714 0.02 0.02 0.02 *** 4717 0.01 0.01 0.07 *** 
2715 0.05 0.02 0.30 0.00 4719 0.04 0.01 0.03 0.04 
*** Not detected
Transitional milk (week 2 post-partum) (µmol/L) 
Subject Lutein  Zea βcry βcar  Subject Lutein  Zea βcry βcar  
2701 0.24 0.11 0.09 0.06 4702 0.14 0.06 0.21 0.08 
2702 0.07 0.03 0.06 *** 4703 0.03 0.01 0.03 0.04 
2703 0.05 0.02 *** *** 4705 0.11 0.04 0.12 0.05 
2704 0.09 0.02 0.07 *** 4706 0.05 0.02 0.03 *** 
2705 0.11 0.06 0.05 0.03 4708 0.04 0.02 0.02 *** 
2706 0.05 0.03 0.10 0.02 4709 0.05 0.02 0.06 0.07 
2707 0.11 0.03 0.08 0.06 4710 0.04 0.02 0.04 0.05 
2708 0.06 0.02 0.03 0.06 4712 0.06 0.04 0.10 0.03 
2709 0.02 0.01 0.05 *** 4713 0.05 0.03 0.18 0.02 
2710 0.04 0.02 0.02 *** 4714 0.04 0.02 0.03 0.02 
2711 0.06 0.03 0.05 *** 4715 0.05 0.04 0.10 0.04 
2713 0.51 0.24 0.72 0.17 4716 0.05 0.02 0.10 *** 
2714 0.03 0.02 0.02 0.03 4717 0.04 0.02 0.05 0.03 
2715 0.05 0.02 0.17 0.02 4718 0.02 0.01 0.02 0.03 
4701 0.15 0.08 0.06 *** 4719 0.06 0.03 0.04 0.08 
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Figure 41. Typical reversed-phase HPLC chromatogram of the carotenoid analysis of a sample of human milk. 
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Table 33. Carotenoid concentrations in human milk during the 4th week of lactation (mature milk, W4). 
Mature milk (week 4 post-partum) (µmol/L) 
Subject Lutein  Zea βcry βcar  Subject Lutein  Zea βcry βcar  
2701 0.08 0.02 0.03 *** 2723 0.04 0.01 0.02 0.02 
2702 0.04 0.02 0.02 *** 2724 0.02 0.01 0.03 *** 
2703 0.04 0.01 0.00 *** 2725 0.05 0.02 0.05 0.02 
2704 0.02 0.00 *** *** 2726 0.04 0.01 0.05 *** 
2705 0.07 0.02 0.05 0.02 2727 0.07 0.02 0.10 *** 
2706 0.02 0.01 0.05 0.03 2728 0.02 0.01 0.09 *** 
2707 0.09 0.03 0.04 *** 2729 0.03 0.01 0.02 *** 
2708 0.04 0.02 0.03 0.05 2730 0.18 0.07 0.09 *** 
2709 0.01 0.01 0.04 *** 2732 0.02 0.01 0.01 *** 
2710 0.06 0.02 0.03 0.02 2733 0.03 0.01 0.01 *** 
2712 0.04 0.01 0.02 0.03 2735 0.04 0.01 0.08 *** 
2713 0.07 0.02 0.13 0.10 2736 0.10 0.04 0.05 *** 
2714 0.02 0.01 0.03 0.06 2737 0.06 0.02 0.07 0.04 
2715 0.04 0.02 0.09 *** 2739 0.12 0.03 0.15 0.06 
4701 0.06 0.03 0.03 0.02 2740 0.08 0.02 0.18 *** 
4702 0.06 0.03 0.06 *** 2741 0.05 0.02 0.07 0.03 
4704 0.03 0.01 0.02 0.02 2742 0.03 0.01 0.04 0.01 
4705 0.05 0.02 0.02 *** 2743 0.05 0.02 0.06 *** 
4706 0.02 0.01 0.02 *** 4720 0.07 0.03 0.05 *** 
4708 0.04 0.02 0.02 0.03 4721 0.02 0.01 0.14 *** 
4709 0.05 0.02 0.06 0.07 4722 0.02 0.01 0.03 *** 
4710 0.05 0.01 0.02 *** 4723 0.06 0.03 0.09 0.04 
4712 0.08 0.04 0.12 0.08 4724 0.03 0.02 0.06 *** 
4713 0.09 0.05 0.12 0.03 4725 0.11 0.02 0.12 0.03 
4714 0.04 0.01 0.03 0.03 4726 0.12 0.04 0.12 *** 
4715 0.05 0.02 0.07 0.06 4727 0.06 0.02 0.12 *** 
4716 0.04 0.02 0.13 0.02 4728 0.05 0.02 0.07 0.02 
4717 0.02 0.02 0.06 0.05 4729 0.04 0.02 0.09 *** 
4718 0.03 0.01 0.02 0.03 4730 0.09 0.03 *** *** 
4719 0.03 0.01 0.02 0.03 4731 0.05 0.03 0.07 *** 
2716 0.03 0.01 0.07 0.02 4732 0.03 0.02 0.02 *** 
2717 0.06 0.02 0.03 *** 4733 0.02 0.01 0.02 *** 
2718 0.03 0.02 0.05 *** 4736 0.08 0.02 0.03 *** 
2719 0.03 0.02 0.07 0.02 4738 0.03 0.02 0.05 *** 
2720 0.05 0.02 0.04 *** 4739 0.03 0.02 0.10 *** 
2721 0.02 0.01 0.04 0.01 4740 0.02 0.01 0.02 *** 
2722 0.02 0.01 0.06 *** 4741 0.07 0.03 0.07 *** 
*** Not detected 
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Table 34. Carotenoid concentrations in maternal serum and milk during the 4th week (W4) after delivery. 
Serum (µmol/L) Milk W4 (µmol/L) 
N Range Concentration Mean ± S.D. Range Concentration Mean ± S.D. r 
Lutein 73 0.12 - 0.69 0.27  ± 0.12 0.01 - 0.18 0.05 ± 0.03 0.429* 
Zea 73 0.05 - 0.27 0.11 ± 0.04 0.01 - 0.07 0.02 ± 0.01 0.361* 
β-cry 71 0.07 - 1.83 0.40 ± 0.32 0.004 - 0.18 0.06 ± 0.04 0.592* 
β-car 26 0.07 - 1.10 0.34 ± 0.23 0.02 - 0.08 0.04 ± 0.02 0.177 
L/Z 73 1.22 - 5.31 2.51  ± 0.72 1.40 – 4.45 2.61  ± 0.67 0.575* 
* p<0.003 
Levels of lutein, zeaxanthin, -cryptoxanthin, and -carotene in maternal milk 
during the three weeks studied were compared to document any longitudinal changes.  
Strong correlations (p<0.001) between lutein and zeaxanthin were observed for all three 
weeks, but no correlation of carotenoid levels with % of fatty acids in milk was observed.  
Values for the concentration of lutein, zeaxanthin, -cryptoxanthin, and -
carotene in maternal milk were compared with those obtained from matched serum 
samples during week 4.  Positive correlations (p<0.003) were observed for lutein, 
zeaxanthin, and -cryptoxanthin concentrations having r values of 0.429, 0.361, and 
0.592, respectively. Lutein and zeaxanthin concentrations were 5.4-5.5 times lower and 
pro-vitamin A carotenoids were more than 6.6 times lower in milk than in maternal 
serum.  The lutein:zeaxanthin ratios were also positively correlated positively between 
milk and serum (r = 0.575, p<0.0001), see Table 34. 
A comparison of carotenoid concentrations in maternal milk during the fourth 
week of study is presented in Table 35 for the same group of subjects.  A two-way 
ANOVA test run for the data shows that the levels of lutein and zeaxanthin are 
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significantly different between transitional milk (W2) and mature milk (W3 and W4).  
Pro-vitamin A carotenoids, -cryptoxanthin and -carotene showed a different pattern. 
Only -cryptoxanthin was significantly decreased in concentration between transitional 
milk (W2) and mature milk during the last week (W4), while -carotene did not show 
any significant change in concentration during the first month.  In the same manner as 
seen in chapter 3, % total fatty acids in milk did not change. A paired t-test run for lutein 
and -cryptoxanthin levels for each week (W2 p=0.28, W3 p=0.11, W4 p=0.62), showed 
that the concentration levels are not statistically different between these two carotenoids 
during the same week. 
For the same subjects lutein, -cryptoxanthin, and -carotene levels are each 
strongly correlated between transitional milk (W2) and mature milk (W4), and between 
W3 and W4 for mature milk.  In the same comparison, no correlation was observed for 
zeaxanthin.  No correlation of the carotenoids with total percent of fatty acids in milk was 
observed during the time of lactation. 
Table 35. Longitudinal, subject by subject comparison of carotenoid concentrations and total fatty acid content between weeks.  Values reported are mean concentrations (mean ± SEM) in µmol/L. 
  Week 2 Week 3 Week 4 
 N Range Conc. Range Conc. Range Conc. Lutein 26 0.20 - 0.51 0.09  ± 0.02 0.10 - 0.13 0.05  ± 0.01 a 0.10 - 0.09 0.05  ± 0.01a 
Zea 26 0.10 -0.24 0.04  ± 0.01 0.10 -0.50 0.02  ± 0.00 a 0.01 -0.50 0.02  ± 0.00 a 
β-cry 22 0.02 - 0.72 0.10  ± 0.03 0.01 - 0.30 0.07  ± 0.02  0.00 - 0.13 0.05 ± 0.02a 
β-car 15 0.02 - 0.17 0.05  ± 0.01 0.00 - 0.10 0.05  ± 0.01 0.02 - 0.10 0.05  ± 0.01 
L/Z 26 1.25 - 4.23 2.32 ± 0.12 1.27 - 3.72 2.28 ± 0.13 1.40 - 4.34 2.53 ± 0.12 
% FA 26 1.23 - 5.58 3.40  ± 0.20 0.78 - 5.28 3.26  ± 0.22  1.20 - 6.43 3.26  ± 0.28 
a Significantly different (p < 0.05) than transitional milk (2nd week, W2).  
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Because the carotenoid level in serum has previously been reported to be 
correlated with maternal BMI carotenoid concentrations in mature milk during week 4 
were grouped according to maternal BMI and are shown in Table 36.  The subjects were 
split in three groups: normal (BMI = 18.5 – 24.9), overweight (BMI = 25.0 – 29.9), and 
obese (BMI > 30.0).  There was no difference in the levels of lutein and zeaxanthin in 
milk between these groups but pro-vitamin A carotenoids levels in maternal milk were 
different between the three groups.  Pro-vitamin A carotenoid concentrations in milk 
decrease as BMI increased.  -cryptoxanthin, a pro-vitamin A carotenoid, showed a 
statistically significant decrease but only between the normal and obese groups. 
Table 36. Carotenoid concentrations (mean ± st.dev., µmol/L) in mature maternal milk (W4) grouped according to the subject’s body mass index. 
 Normal Overweight Obese N 17 32 19 
BMI 23.18 ± 1.36a 27.49 ± 1.35 32.85 ± 2.87 
Lutein  0.05 ± 0.03 0.05 ± 0.03 0.05 ± 0.02 
Zeaxanthin 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 
β-cryptoxanthin 0.08 ± 0.04b 0.06 ± 0.04 0.05 ± 0.03 
β-carotene 0.05 ± 0.03 (N = 8) 
0.04 ± 0.02 
(N = 13) 
0.03 ± 0.01 
(N = 9) 
% total FA 3.72 ± 1.64 3.76 ± 1.13 4.04 ± 1.70 
a Significantly different (p < 0.001) than overweight and obese group. b Significantly different (p < 0.05) than obese group.  
Pearson correlation coefficients obtained for a subject by subject correlation of 
the individual lutein, zeaxanthin, -cryptoxanthin, and -carotene concentrations in 
human milk with the concentrations of the individual fatty acids in all three weeks 
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reported in Chapter 3 were determined.  Tables 37 and 38 show those results that had a 
statistically significant correlation between concentrations any of the FAs and any of the 
carotenoids studied in milk.  
Table 37. Pearson correlation coefficients obtained from the subject by subject comparison of carotenoid concentrations and individual fatty acid concentrations in transitional milk (W2). 
 Week 2 
 N C14:0 C16:0 C20:1n-9 C24:1n-9 C20:2n-6 C18:2n-6 C18:3n-3 
Lutein 30 r = 0.486 p = 0.006 r = 0.375 p = 0.04 r = 0.459 p = 0.01 r = 0.366*  p = 0.07 r = 0.331*  p = 0.07 r = -0.432 p = 0.02 r = -0.435 p = 0.02 
Zea 30 r = 0.468 p = 0.009 r = 0.381 p = 0.04 r = 0.468 p = 0.009 r = 0.377  p = 0.04 r = 0.341* p = 0.06 r = -0.423 p = 0.02 r = -0.418 p = 0.02 
β-cry 29 r = 0.483 p = 0.008 N.S.C. N.S.C. r = 0.388  p = 0.04 r = 0.477  p = 0.009 r = -0.384 p = 0.04 r = -0.312 p = 0.099 
β-car 20 r = 0.453 p = 0.04 N.S.C. r = 0.436 p = 0.05 r = 0.432* p = 0.06 N.S.C. r = -0.489 p = 0.03 r = -0.569 p = 0.009 
N.S.C = no significant correlation was observed. * correlation approaches significance. 
A comparison of SFA levels with carotenoids levels reveals a positive correlation 
for all carotenoids reported here in transitional milk (W2) with myristic acid (C14:0).  
Only lutein and zeaxanthin showed a positive correlation with palmitic acid (C16:0) in 
transitional milk (W2).  In a comparison of MUFAs with carotenoid concentrations, 
lutein, zeaxanthin, and -carotene were all found to be positively correlated with 
eicosenoic acid (C20:1n-9) in transitional milk (W2).  Analysis also shows that all 
carotenoids except -carotene are significantly and positively correlated with nervoic 
acid (C24:1n-9) in transitional milk (W2).  Although -carotene did not reach a 
significant statistical level it was trends positively with this fatty acid in transitional milk.   
  
106  
Comparison of the levels of individual PUFAs in transitional milk (W2), reveals 
that eicosadienoic acid (C20:2n-6) is positive correlated with lutein, zeaxanthin and -
cryptoxanthin, but zeaxanthin, although positively correlated does not reach a statistically 
significant level.  The essential fatty acids linoleic (C18:2n-6) and α-linoleic acid 
(C18:3n-3) were found to be significantly inversely correlated with all carotenoids 
measured in this study in transitional milk (W2). 
Table 38. Pearson correlation coefficients obtained from the subject by subject comparision of carotenoid concentrations and individual fatty acid concentrations in in mature milk (W3 and W4). 
Week 3 Week 4 
 N C14:0 C18:1n-9 C20:0 N C20:1n-9 C20:2n-6 C24:0 
Lutein  28 r = 0.336 p = 0.008 r = -0.370 p = 0.05 N.S.C. 73 N.S.C. N.S.C. N.S.C. 
Zea 28 N.S.C. N.S.C. N.S.C. 73 r = 0.209* p = 0.08 N.S.C. r = 0.258 p = 0.03 
β-cry 24 N.S.C. N.S.C. r = -0.755 p = 0.000 71 r = 0.291 p = 0.01 r = 0.316 p = 0.007 N.S.C. 
β-car 16 r = 0.674 p = 0.004 r = -0.501 p = 0.048 N.S.C 31 r = 0.436 p = 0.05 N.S.C. N.S.C. 
N.S.C = no significant correlation was observed. *Correlation approaches significance.   
 In mature milk (W3), myristic (C14:0) is significantly and positively correlated 
with lutein and -carotene concentrations.  Arachidic acid (C20:0) was found to 
positively correlate significantly only with -cryptoxanthin.  Oleic acid (C18:1n-9), was 
the only MUFA to have an inverse correlation only with lutein and -carotene.  
Zeaxanthin did not show a correlation with any individual fatty acids during week 3.  By 
contrast, in mature milk (W4), only zeaxanthin correlated positively and significantly 
with the lignoceric acid (C24:0).  Zeaxanthin, -cryptoxanthin, and -carotene all 
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positively correlate with eicosenoic acid (C20:1n-9) levels, although zeaxanthin did not 
reach a statistically significant level.  Eicosadienoic acid (C20:2n-6) was the only PUFA 
that was revealed to be positively correlated with -cryptoxanthin in mature milk (W4).  
Lutein was not found to be correlated with any individual fatty acid in mature milk 
during week 4. 
4.3. Discussion and Conclusions 
 
Figure 42. Carotenoid concentrations (mean ± SEM) in µmol/L during the first month post-partum (data from Table 25). 
 
A longitudinal decrease in carotenoid levels in human milk has been previously 
observed, with highest levels found in colostrum and the lowest in mature milk [135, 
147].  We found that the most abundant carotenoids in the milk from the population of 
women in our study are lutein and -cryptoxanthin.  This apparent equivalence in the 
levels of the two carotenoids as seen in Figure 42 obscures an underlying and interesting 
difference.  Although the average values of lutein and -cryptoxanthin are nearly the 
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same it is interesting to note that the -cryptoxanthin levels are higher in 63 % of all 
subjects in the study, see Table 33.     
 
Figure 43. Comparison of pro-vitamin A carotenoids by BMI group (data from Table 26). Concentrations (mean ± standard deviation).  
* significantly different than normal group (p=0.03).  
 
For data obtained for mature milk during week 4 we note that when grouped by 
BMI, see Table 26, the concentration of -cryptoxanthin was found to be highest (0.08 ± 
0.04) in the normal BMI group, as compared to the overweight and obese groups, see 
Figure 43.  These differences in carotenoid levels for those subjects with lower versus 
higher BMI’s are consistent with the reports that linked serum carotenoid levels with 
BMI.  -Cryptoxanthin is converted to vitamin A in adipose tissue. For subjects having 
high BMI values, -Cryptxanthin would be taken up from serum and metabolized, 
reducing amounts in these subjects available for transport into milk. We attribute the 
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time to originate in this difference in the -cryptoxanthin levels with BMI a trend that 
does not exist for lutein.  If -cryptoxanthin were not metabolized it would presumably 
be found in higher concentrations for all subjects.  
 
Figure 44. Composition of carotenoids in serum and mature milk during the 4th week post-partum. 
 
When comparing the percent composition of carotenoids in serum and milk, we 
observed that the concentration of lutein, relative to the other carotenoids, is higher in 
milk than in serum, see Figure 44. The proportion of lutein in mother’s milk is higher 
than that in serum by a factor of 5.4, and the carotenoid concentration in milk is about 5-7 
times less than in serum.  Gossage et al.[152] studied the carotenoid composition in 
plasma of 16 lactating women and showed that the levels of lutein decreased between day 
4th and day 32nd post-partum.  That the lutein concentration decreases in serum while 
increasing in maternal milk, is evidence of an increased efficiency in maternal transfer of 
lutein from plasma to milk during the first month post-partum.  In addition to our results, 
the study by Sherry et al.[153] reported that the levels of lutein and zeaxanthin were most 
  
110  
abundant in breast milk (4-6 weeks post-partum) although the concentrations in milk 
tended to decrease over the study period (6 weeks).  They did not see a change in 
maternal plasma during the period.  These outcomes reveal that lutein is actively 
transported into milk during early stages of lactation (during the first month), after that 
the levels slowly decrease and reach a constant level.  Even though the level of lutein 
decreases slowly in secreted milk, the active mobilization of the carotenoid appears to 
work against this trend as the mother’s body-stores of carotenoids diminish providing the 
infant a the maximal amount of this nutritionally significant carotenoid.    
Total fatty acids in human milk (principally present as triglycerides) do not 
decrease with time during lactation.  This contrasts with the trend for carotenoids, shown 
previously in Chapter 3.  Consequently, we do not find a correlation between the total % 
fatty acid and carotenoid levels.   The overall transport of fatty acids from plasma into 
human milk does not account for a simple mechanism that controls transport of 
carotenoids during early lactation, despite the common lipophilic characteristics of both 
carotenoids and fatty acids.  The mechanism of transport of carotenoids appears be 
regulated by factors other than those controlling total triglycerides in milk.  Evidence 
from carotenoid levels during early lactation (in colostrum and to some extent transitional 
milk) indicates that carotenoid transport during this period may be controlled by different 
factors than in mature milk.  
It is accepted that the source of carotenoids secreted into milk is largely the 
circulating maternal blood supply.  To a large extent this is also true of many individual 
fatty acids including those considered essential.  Although carotenoid concentrations do 
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not correlate with total fat percentages in milk, strong correlations were found between 
carotenoid concentrations in maternal serum and milk (see Table 34).  Essential fatty 
acids originate from dietary intake and to a lesser extent from mobilization from body 
stores. Their concentrations in milk are therefore, like carotenoids, dependent upon serum 
levels.  In contrast to these essential fatty acids, many other fatty acids can be synthesized 
in situ by the mammary gland and/or by the liver in addition to originating from diet.  
Also depending on metabolic rates, their secreted concentrations in milk can be 
uncoupled from dietary intake and to an extent from serum concentrations.   
 
Figure 45. Relation of essential fatty acids with lutein and zeaxanthin in transitional milk. 
 
We find that the concentrations of a small number of individual fatty acids do 
correlate, some positively, others negatively, with carotenoid concentrations in human 
milk, see Tables 7 and 8.   Different classes of lipids differ in their physical and chemical 
properties the mechanisms of their transport into milk also differ at the molecular level.  
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Our analysis shows the most statistically significant correlations between fatty acids and 
carotenoids are found in transitional milk (W2) as opposed to mature milk (W3 & W4).  
In transitional milk, all four carotenoids measured in this study were positively correlated 
with myristic acid.  Myristic acid originates from de novo synthesis in the mammary 
glands and liver.  Only the non pro-vitamin A xanthophylls, lutein and zeaxanthin, were 
found to have a positive correlation with palmitic acid, which can likewise originate from 
de novo synthesis, but is also abundant in the diet.  We observed an inverse correlation of 
lutein and zeaxanthin with the essential fatty acids, linoleic acid and α-linoleic acid.  As a 
consequence, higher concentrations of lutein and zeaxanthin are likely present when 
lower concentrations of these two essential fatty acids are present in maternal milk, see 
Figure 45.  Lutein and zeaxanthin are known to be carried by high density lipoproteins in 
the circulating system.  The inverse relationship between the carotenoids and the essential 
fatty acids suggests the possibility of a competition between these fats and the lutein and 
zeaxanthin for a critical transport step.  HDL may have a limited transport capacity, and 
in the presence of high levels of essential PUFA, the capacity to transport carotenoids 
may be diminished.  Another potential relationship that could link carotenoid levels and 
these fatty acids may be through the events associated with oxidative stress.  N-6 fatty 
acids can potentiate oxidative processes and ROS production, leading to degradation of 
carotenoids.  Further studies will be necessary to further investigate the possibility of a 
mechanistic association between these individual fatty acids and carotenoids. 
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SUMMARY  
We have reported the concentrations of 29 fatty acids in maternal milk.  Special 
attention was given to the essential polyunsaturated fatty acids since they are known to 
play an important role in early development.  In general, n-3 and n-6 polyunsaturated 
fatty acids were found to be abundant in maternal milk, which is a nutritional advantage 
for the new-born. The levels of these fatty acids are in accordance with the World Health 
Organization guidelines for intake by infants and values reported for other countries.  
Concentrations of individual fatty acids in this population, when compared with other 
previously studied groups, reveals a number of new trends.  The DHA (0.78%w/w) 
concentration in the milk of these Peruvian women was found to fall into the highest 
quartile group among the 29 different countries studied.  
 
 
Figure 46. Carotenoid concentration in maternal milk, serum, and cord blood. Concentration (mean ± S.E.M.). Serum, n=74; milk W2, n=30; milk W3, n=28; milk W4, n=74; and cord blood, n=26. 
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Our measurements of the concentrations of carotenoids in maternal milk, maternal 
serum, and cord blood confirm that maternal serum concentrations are consistently higher 
than either cord blood or maternal milk concentrations. Although concentrations in 
maternal milk decrease with time post-partum, lutein:zeaxanthin ratios remain constant.  
Maternal serum carotenoid concentrations correlate with both cord blood and maternal 
milk concentrations.   
We observed that the proportion of lutein in serum decreases as a fraction of total 
carotenoids during the first month, whereas in maternal milk the proportion of lutein 
increases during this period.  Our results suggest that lutein is actively transported into 
maternal milk. Body mass index (BMI) influenced the concentration of pro-vitamin A 
carotenoids in milk and serum, but did not have a comparable effect on the concentration 
of the xanthophylls, lutein and zeaxanthin.  For individuals with high BMI levels, pro-
vitamin A concentrations in maternal milk are lower than those with normal adiposity 
whereas lutein and zeaxanthin are identical in these two groups of women. 
No correlation is found between % total fat in milk and carotenoid levels.  The 
transfer of carotenoids from the maternal blood stream into milk is not controlled by a 
simple relationship with total fat in milk.  We found a significant inverse correlation 
between lutein and the essential fatty acids, linoleic and α-linoleic acid in transitional 
milk.  A competition for transport between these the fatty acids and lutein is suggested by 
this relationship.  Lutein and zeaxanthin concentrations in transitional milk (2nd week 
post-partum) are found to be higher when linoleic and α-linoleic acids are lower in 
concentration.  The inverse relationship is observed in mature milk during the 4th week of 
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lactation.  In mature milk the lutein concentration is lower and we observe that linoleic 
and α-linoleic acids have high concentrations, see Figure 47.  A paired t-test showed that 
lutein, zeaxanthin and α-linoleic acid concentrations are statistically significantly 
different between transitional and mature milk (p < 0.05).  Linoleic acid showed had the 
same trend but it was not statistically significant (p = 0.07).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Lutein, zeaxanthin, α-linoleic (ALA), and linoleic acid (LA) variations (mean ± SEM) between transitional and mature milk. *significantly different than mature milk (p < 0.05).  
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This is the first time a study has presented data comparing carotenoid 
concentrations to those of individual fatty acids in maternal milk.  We conclude that 
carotenoid transport into milk during the early stages of lactation (colostrum and 
transitional milk) is influenced by different physiological factors than in mature milk.  
Although based on a limited sample, this study points to the need for further investigation 
into the association between individual fatty acids and carotenoid levels which may shed 
light on the relationship between transport of individual fatty acids and carotenoids.     
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APPENDICES 
1. Fatty acids in human milk found in countries in South and North America. 
 
North America Canada US Mexico South America Chile Argentina Bolivia Brazil 
Author Yuhas Yuhas Yuhas Author Yuhas Marin Martin Nishimura lactation stage mature mature mature lactation stage mature 15day-3months     
N 48 49 46 N 50 35 35 47 
C12:0 5.25 4.40 4.97 C12:0 6.15 5.10 5.72 7.46 C14:0 5.84 4.91 5.57 C14:0 6.80 6.07 9.81 6.81 C16:0 18.67 19.26 19.91 C16:0 18.79 21.23 24.96 19.50 C18:0 5.83 6.21 6.07 C18:0 5.77 10.55 5.54 5.82 total SFA 38.47 37.41 39.16 total SFA 40.65 45.12 42.67             C16:1n-7 2.79 2.64 2.64 C16:1n-7 2.70 2.78 6.06 2.11 C16:1n-9 0.23 0.44 0.35 C16:1n-9 0.40 0.43   C18:1n-9 35.18 32.77 30.79 C18:1n-9 26.19 31.10 27.50 26.46 C20:n-9 0.52 0.39 0.42 C20:n-9 0.55 0.11 0.10 0.12 total MUFA 42.89 40.40 38.11 total MUFA 33.71 34.41 31.20             C18:2n-6 LA 11.48 14.78 16.05 C18:2n-6 LA 17.75 17.56 10.23 20.96 C20:3n-6 0.27 0.35 0.33 C20:3n-6 0.44 0.42 0.47 0.34 C20:4n-6 AA 0.37 0.45 0.42 C20:4n-6 AA 0.42 0.48 1.06 0.48 total n-6 13.42 17.19 18.26 total n-6 20.28 19.60 12.47 21.87             C18:3n-3 ALA 1.22 1.05 1.05 C18:3n-3 ALA 1.14 0.48 1.90 1.54 C20:5n-3 EPA 0.08 0.07 0.07 C20:5n-3 EPA 0.09 0.11 0.20 0.08 C22:6n-3 DHA 0.17 0.17 0.26 C22:6n-3 DHA 0.43 0.14 0.69 0.09 
total n-3 1.77 1.56 1.69 total n-3 2.05 0.85 3.44 2.11 
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2.  Fatty acids in human milk found in countries in Europe 
Europe UK Sweden Germany Spain Portugal Italy France Croatia Serbia Hungary 
Author Yuhas  Zetterstrom Genzel-Boroviczeny  Lopez-Lopez Ribeiro Serra Pugo-Gunsan Kresic Arsic Dekci 
lactation stage mature 1st month 30th day >2 weeks 4 weeks 14,21,28 day 42th day 3 months 14th day mature 
N 44 19 15 40 31 20 15 83 23 15 
C12:0 4.99 3.56 6.28 4.55 5.51 6.48 
C14:0 5.87 5.98 7.39 6.00 5.36 10.69 7.49 7.44 
C16:0 22.59 25.19 22.76 19.48 22.14 29.26 25.93 22.24 
C18:0 6.25 1.17 7.47 6.25 5.93 5.55 7.09 6.45 
total SFA 42.94 40.66 40.42 45.50 48.23 32.60 44.30 39.79 
  
C16:1n-7 2.85 1.78 0.10 2.57 
C16:1n-9 0.44 2.69 0.42 2.50 
C18:1n-9 33.28 39.90 30.74 36.35 27.34 39.93 33.19 43.00 32.78 
C20:n-9 0.44 0.64 0.60 0.40 0.41 1.04 
total MUFA 40.78 43.74 39.63 33.23 42.69 36.78 36.56 39.26 
  
C18:2n-6 LA 10.45 10.29 11.81 16.59 16.20 9.79 11.81 16.30 16.29 15.23 
C20:3n-6 0.33 0.37 0.41 0.48 0.45 0.25 0.25 0.57 0.35 
C20:4n-6 AA 0.36 0.42 0.46 0.53 0.52 0.47 0.24 0.40 0.51 0.51 
total n-6 12.42 11.67 18.33 18.09 11.08 12.64 18.20 18.24 
  
C18:3n-3 ALA 1.22 1.25 0.74 0.75 0.66 0.36 0.55 1.40 0.49 0.70 
C20:5n-3 EPA 0.11 0.06 0.12 0.10 0.16 0.09 0.03 0.10 0.04 
C22:6n-3 DHA 0.24 0.28 0.32 0.15 0.42 0.12 0.14 0.20 0.19 0.22 
total n-3 1.94 1.64 1.38 1.42 0.74 1.05 1.70 0.86 
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3. Fatty acids in human milk found in countries in Africa and Oceania. 
 
Africa Nigeria rural Nigeria urban Mauritus Oceania Australia  Australia 
Author Glew Glew Pugo-Gunsan  Author  Yuhas  Gibson 
lactation stage     42nd day lactation stage   30th day 
N 41 41 13 N 48 23 
C12:0 10.10 10.01 7.19 C12:0 5.49 C14:0 13.50 13.5 6.96 C14:0 6.28 C16:0 25.00 25.3 18.51 C16:0 22.26 C18:0 4.50 5 4.97 C18:0 6.77 total SFA 57.10 56.52 40.21 total SFA 43.79 47.21     C16:1n-7 2.00 1.7 1.95 C16:1n-7 2.97 C16:1n-9 0.07 0.06 C16:1n-9 0.42 C18:1n-9 27.90 29.2 23.01 C18:1n-9 32.23 C20:n-9 0.22 C20:n-9 0.38 total MUFA 25.56 total MUFA 36.48     C18:2n-6 LA 7.80 7 26.85 C18:2n-6 LA 10.66 13.56 C20:3n-6 0.13 0.11 0.46 C20:3n-6 0.31 0.44 C20:4n-6 AA 0.62 0.48 0.48 C20:4n-6 AA 0.38 0.45 total n-6 28.55 total n-6 12.74     C18:3n-3 ALA 0.80 0.77 2.65 C18:3n-3 ALA 0.90 0.89 C20:5n-3 EPA 0.07 0.08 0.12 C20:5n-3 EPA 0.10 0.07 C22:6n-3 DHA 0.15 0.4 0.38 C22:6n-3 DHA 0.23 0.26 
total n-3 3.65 total n-3 2.28  
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4. Fatty acids in human milk found in countries in Asia and South Asia. 
 
Asia China North China Japan South Asia Phillipines 
West India Urban  Nepal 
Author Yuhas Wan Yuhas Author Yuhas Roy Glew 
lactation stage mature 9-12 week mature lactation stage mature 2nd-3th week 2nd-4th week 
N 50 52 51 N 54 62 48 
C12:0 4.24 4.71 5.86 C12:0 13.82 2.43 12.00 C14:0 3.61 3.92 6.11 C14:0 12.12 3.67 10.50 C16:0 18.62 18.68 20.20 C16:0 23.02 20.48 21.70 C18:0 6.13 5.63 6.14 C18:0 4.75 3.85 4.88 total SFA 35.13 35.92 41.51 total SFA 57.06 35.13 52.60     C16:1n-7 1.88 1.29 2.56 C16:1n-7 4.59 2.64 2.76 C16:1n-9 0.49 0.36 C16:1n-9 0.08 C18:1n-9 36.49 31.26 31.43 C18:1n-9 21.85 28.35 25.50 C20:n-9 1.25 0.52 C20:1n-9 0.28 0.84 2.22 total MUFA 43.90 32.59 38.43 total MUFA 30.33 34.03 34.40     C18:2n-6 LA 14.88 17.73 12.66 C18:2n-6 LA 7.90 11.05 7.91 C20:3n-6 0.28 0.23 0.25 C20:3n-6 0.31 0.65 0.31 C20:4n-6 AA 0.49 0.30 0.40 C20:4n-6 AA 0.39 0.65 0.35 total n-6 16.72 18.75 14.42 total n-6 9.47 13.59 10.00     C18:3n-3 ALA 2.02 1.03 1.33 C18:3n-3 ALA 0.43 1.68 1.93 C20:5n-3 EPA 0.07 0.26 C20:5n-3 EPA 0.15 0.39 0.13 C22:6n-3 DHA 0.35 0.19 0.99 C22:6n-3 DHA 0.74 0.72 0.21 
total n-3 2.90 1.22 3.10 total n-3 1.71 3.65 2.44                  
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5. Fatty acids in human milk found in countries in Middle East. 
Middle east West Iran Iraq Suburban Israel Turkey 
Author Bahrami Al-Tamer Saphier Aydin 
lactation stage   5th mo 2nd-3rd mo 28th day 
N 52 25 29 15 
C12:0 9.67 6.91 C14:0 14.97 9.60 C16:0 22.09 21.40 23.05 C18:0 5.23 8.45 total SFA 41.30 55.71 43.00 51.56   C16:1n-7 3.09 1.64 C16:1n-9 C18:1n-9 30.90 23.53 31.30 13.31 C20:1n-9 0.86 total MSFA 29.62 33.50 17.17   C18:2n-6 LA 13.80 11.55 20.00 25.58 C20:3n-6 0.63 C20:4n-6 AA 1.40 0.16 0.44 1.81 total n-6 11.79 29.43   C18:3n-3 ALA 1.10 0.20 2.00 1.20 C20:5n-3 EPA 0.20 0.06 0.08 C22:6n-3 DHA 0.12 0.17 0.52 
total n-3 0.38 1.85  
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